High level, long term delivery of oxytetracycline HC1 from a controlled release device in an artificial rumen by Ferguson, Thomas Harry
Retrospective Theses and Dissertations Iowa State University Capstones, Theses andDissertations
1981
High level, long term delivery of oxytetracycline
HC1 from a controlled release device in an artificial
rumen
Thomas Harry Ferguson
Iowa State University
Follow this and additional works at: https://lib.dr.iastate.edu/rtd
Part of the Biomedical Engineering and Bioengineering Commons
This Dissertation is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University
Digital Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University
Digital Repository. For more information, please contact digirep@iastate.edu.
Recommended Citation
Ferguson, Thomas Harry, "High level, long term delivery of oxytetracycline HC1 from a controlled release device in an artificial rumen
" (1981). Retrospective Theses and Dissertations. 7165.
https://lib.dr.iastate.edu/rtd/7165
INFORMATION TO USERS 
This was produced from a copy of a document sent to us for microfilming. While the 
most advanced technological means to photograph and reproduce this document 
have been used, the quality is heavily dependent upon the quality of the material 
submitted. 
The following explanation of techniques is provided to help you understand 
markings or notations which may appear on this reproduction. 
1.The sign or "target" for pages apparently lacking from the document 
photographed is "Missing Page(s)". If it was possible to obtain the missing 
page(s) or section, they are spliced into the film along with adjacent pages. 
This may have necessitated cutting through an image and duplicating 
adjacent pages to assure you of complete continuity. 
2. When an image on the film is obliterated with a round black mark it is an 
indication that the film inspector noticed either blurred copy because of 
movement during exposure, or duplicate copy. Unless we meant to delete 
copyrighted materials that should not have been filmed, you will find a good 
image of the page in the adjacent frame. If copyrighted materials were 
deleted you will find a target note listing the pages in the adjacent frame. 
3. When a map, drawing or chart, etc., is part of the material being photo­
graphed the photographer has followed a definite method in "sectioning" 
the material. It is customary to begin filming at the upper left hand corner of 
a large sheet and to continue from left to right in equal sections with small 
overlaps. If necessary, sectioning is continued again—beginning below the 
first row and continuing on until complete. 
4. For any illustrations that cannot be reproduced satisfactorily by xerography, 
photographic prints can be purchased at additional cost and tipped into your 
xerographic copy. Requests can be made to our Dissertations Customer 
Services Department. 
5. Some pages in any document may have indistinct print. In all cases we have 
filmed the best available copy. 
University 
Microfilms 
International 
300 N, ZEEB RD., ANN ARBOR, Ml 48106 
8122512 
FERGUSON, THOMAS HARRY 
HIGH LEVEL, LONG TERM DELIVERY OF OX^TETRACYCLINE 
HYDROCHLORIDE FROM A CONTROLLED RELEASE DEVICE IN AN 
ARTIFICIAL RUMEN 
Iowa State University PH.D. 1981 
University 
Microfilms 
I nt6r n at io n Sll 300 N. Zeeb Road. Ann Arbor, MI 48106 
PLEASE NOTE: 
In all cases this material has been filmed in the best possible way from the available copy. 
Problems encountered with this document have been identified here with a check mark V . 
1. Glossy photographs or pages 
2. Colored illustrations, paper or print ^ 
3. Photographs with dark background ^ 
4. Illustrations are poor copy 
5. Pages with black marks, not original copy 
6. Print shows through as there is text on both sides of page 
7. Indistinct, broken or small print on several pages 
8. Print exceeds margin requirements 
9. Tightly bound copy with print lost in spine 
10. Computer printout pages with indistinct print 
11. Page(s) lacking when material received, and not available from school or 
author. 
12. Page(s) seem to be missing in numbering only as text follows. 
13. Two pages numbered . Text follows. 
14. Curling and wrinkled pages 
15. Other 
University 
Microfilms 
International 
High level, long term delivery of oxytetracycline HCl from a 
controlled release device in an artificial rumen 
A Dissertation Submitted to the 
Graduate Faculty in Partial Fulfillment of the 
Requirements for the Degree of 
DOCTOR OF PHILOSOPHY 
Major: Biomedical Engineering 
by 
Thomas Harry Ferguson 
Approved: 
Professor-in-charge, 
Program in Biomedical Engineering 
For jft^ JSduate College
Iowa State University 
Ames, Iowa 
1981 
Signature was redacted for privacy.
Signature was redacted for privacy.
Signature was redacted for privacy.
i i  
TABLE OF CONTENTS 
Page 
LIST OF SYMBOLS ix 
INTRODUCTION 1 
LITERATURE REVIEW 7 
DELIVERY DEVICE THEORY AND ANALYSES 14 
Brooke and Washkuhn Delivery Device: Analysis of Lipper 
and Higuchi 14 
Deviations from the Analysis of Lipper and Higuchi 18 
Corrected analysis 18 
Dissolution controlled mass transfer 20 
Determination of the Concentration Boundary Layer 21 
Analysis of Brooke and Washkuhn Experimental Data 26 
Current Delivery Device Theory 29 
Summary 35 
EXPERIMENTAL PROCEDURES 37 
Artificial Rumen Fabrication 37 
Measurement of Oxytetracycline HCl Concentrations 41 
Compression of Oxytetracycline HCl: Density Measurement 42 
Solubility of Oxytetracycline HCl in Artificial Rumen Fluid 43 
Diffusion Coefficient Estimation 44 
Delivery Device Fabrication 47 
In Vitro Model for Drug Delivery Measurement 49 
RESULTS AND DISCUSSION 53 
Measurement of Oxytetracycline HCl Concentrations 53 
Solubility of Oxytetracycline HCl in Artificial Rumen Fluid 61 
i i i 
Page 
Diffusion Coefficient Estimation 61 
Prototype #1 62 
Prototype #2 69 
Prototype #3 75 
Discussion of Observations 81 
Artificial Rumen Viability 90 
pH 90 
Volatile fatty acid production 90 
Summary 108 
CONCLUSIONS 109 
RECOMMENDATIONS FOR FUTURE RESEARCH 111 
LITERATURE CITED 114 
ACKNOWLEDGMENTS 120 
APPENDIX: ARTIFICIAL FLUID COMPOSITIONS 121 
iv 
LIST OF TABLES 
Page 
Table 1. Antibiotics used in feedlot cattle for feed efficiency 
and growth promotion (Trenkle, 1977) 2 
Table 2. Common methods for controlled release of agents and 
references 8 
Table 3. Brooke and Washkuhn (1977) delivery device parameters, 
Lipper and Higuchi (1977) parameters, and parameters 
derived in mass transfer coefficient, k, analysis 27 
Table 4. Summary of raw data and regression analysis for fresh 
solutions of compressed drug in artificial rumen fluid 55 
Table 5. Summary of raw data and regression analysis for fresh 
solutions of powdered drug in rumen fluid 57 
Table 6. Summary of raw data and regression analysis for fresh 
solutions of compressed drug in rumen fluid 59 
Table 7. Experimental data for the determination of the diffu­
sion coefficient of compressed oxytetracycline HCl 
in artificial rumen fluid at 38.3°C 63 
Table 8. Theoretical release kinetics for prototype #1 64 
Table 9. Experimental release of oxytetracycline HCl from 
prototype #1 68 
Table 10. Theoretical release kinetics for prototype #2 71 
Table 11. Experimental release of oxytetracycline HCl from 
prototype #2 74 
Table 12. Theoretical release kinetics of prototype #3 77 
Table 13. Experimental release of oxytetracycline HCl from 
prototype #3 80 
Table 14. Summary of oxytetracycline HCl release kinetics for 
prototypes #1-3 and of composite of all data 85 
Table 15. pH data for artificial rumens I-IV 91 
Table 16. Volatile fatty acid concentration data for artificial 
rumens I-IV 97 
V 
Page 
Table 17. Mean concentration levels and relative proportions of 
volatile fatty acids from artificial rumens I-IV 100 
Table Al. Composition of McDougalTs (1948) saliva 121 
Table A2. Composition of the saliva used in current investigation 121 
Table A3. Acid composition of artificial rumen solution 122 
vi 
LIST OF FIGURES 
Page 
Figure 1. Cross section of a zero-order device charged with: 
a. solid drug; b. polymeric matrix containing 
suspended drug (Brooke and Washkuhn, 1977) 10 
Figure 2. Cross sectional view of the device's drug containing 
cavity. The case where the charge of solid drug is 
partially dissolved is illustrated 15 
Figure 3. Velocity and concentration profiles due to flow past 
a soluble flat plate at zero incidence. The velocity 
boundary layer (6(x)) and concentration boundary layer 
(h(x)) are shown 23 
Figure 4. Cross sectional view of the device used in the current 
investigation. The charge of solid drug is partially 
dissolved 30 
Figure 5. Release rate as a function of X. The values used for 
h/n, assuming n = 0.01 cm, are: h/n = 0.2 (o), h/n 
= 1.0 (A), and h/n = 2.5 (A) for 0 = IT radians 34 
Figure 6. Photograph of in vitro rumen showing internal con­
tents. Stirred contents (A), gas bubbles (B), and 
food cap (C) are shown 39 
Figure 7. Photograph of six in vitro rumens in operation 
showing general overall setup 39 
Figure 8. Photograph of prototypes #1-3. Scale bar = 1 cm 48 
Figure 9. Model for measuring drug release from delivery devices 
in the in vitro rumens 50 
Figure 10. Profile of the linear regression analysis for fresh 
solutions of compressed oxytetracycline HCl in 
artificial rumen fluid. The 95% confidence bounds 
are given as dashed lines. Selected points from 
Table 4 are shown 56 
Figure 11. Profile of the linear regression analysis for fresh 
solutions of powdered oxytetracycline HCl in rumen 
fluid. The 95% confidence bounds are given as dashed 
lines. Selected points from Table 5 are shown 58 
v i l  
Page 
Figure 12. Profile of the linear regression analysis for fresh 
solutions of compressed oxytetracycline HCl in rumen 
fluid. The 95% confidence bounds are given as dashed 
lines. Selected points from Table 6 are shown 60 
Figure 13. Theoretical and experimental mass of oxytetracycline 
HCl released versus time for prototype #1. Selected 
points from Table 8 are shown. Regression analysis 
is shown for each data set. Theoretical data (•). 
Experimental data (A) 65 
Figure 14. Theoretical and experimental release rates versus time 
for prototype #1. Selected points from Table 8 are 
shown. Theoretical data (•). Experimental data (A) 66 
Figure 15. Theoretical and experimental mass of oxytetracycline 
HCl released versus time for prototype #2. Selected 
points from Table 10 are shown. Regression analysis 
is shown for each data set. Theoretical data (•). 
Experimental data (A) 72 
Figure 16. Theoretical and experimental release rates versus time 
for prototype #2. Selected points from Table 10 are 
shown. Theoretical data (•). Experimental data (A) 73 
Figure 17. Theoretical and experimental mass of oxytetracycline 
HCl released versus time for prototype #3. Selected 
points from Table 12 are shown. Regression analysis 
is shown for each data set. Theoretical data (•). 
Experimental data (A) 78 
Figure 18. Theoretical and experimental release rates versus time 
for prototype #3. Selected points from Table 12 are 
shown. Theoretical data (•). Experimental data (A) 79 
Figure 19. Photograph of cross section of delivery device proto­
type showing yellow granular material (arrow) in 
the device cavity. Scale bar = 0.20 cm 83 
Figure 20. Composite experimental regression line showing amount 
of oxytetracycline HCl released from prototypes #1-3. 
The 95% confidence bounds are given as dashed lines. 
Points from Tables 9, 11, and 13 are shown. Prototype 
#1 (•). Prototype #2 (o). prototype #3 (•) 87 
Figure 21. pH of control rumen III 93 
Figure 22. pH of rumen I: delivery prototype #1 94 
VI11  
Figure 23. pH of rumen II: delivery prototype #2 
Figure 24. pH of rumen IV: delivery prototype #3 
Figure 25. Acetic acid concentration in artificial rumens I-IV. 
Rumen III: control (•). Rumen I: delivery proto­
type #1 ( O ) .  Rumen I I :  del ivery prototype #2 (A ) .  
Rumen IV: delivery prototype #3 (a) 
Figure 26. Propionic acid concentration in artificial rumens 
I-IV. Rumen III: control (•). Rumen I: delivery 
prototype #1 (o). Rumen II; delivery prototype #2 
(A). Rumen IV: delivery prototype #3 (•) 
Figure 27. Butyric acid (iso + n) concentration in artificial 
rumens I-IV. Rumen III: control (•). Rumen I: 
delivery prototype #1 (o). Rumen II: delivery 
prototype #2 (A). Rumen IV: delivery prototype 
#3 (o) 
Figure 28. Valeric acid (iso + n) concentration in artificial 
rumens I-IV. Rumen III: control (•). Rumen I: 
delivery prototype #1 (o). Rumen II: delivery 
prototype #2 (A). Rumen IV: delivery prototype 
#3 (a) 
Figure 29. Caproic acid concentration in artificial rumens I-IV. 
Rumen III: control (•). Rumen I: delivery proto­
type # 1  ( O ) .  Rumen I I :  del ivery prototype #2 (A ) .  
Rumen IV: delivery prototype #3 (•) 
Figure 30. Phenyl acetic acid concentration in artificial rumens 
I-IV. Rumen III: control (•). Rumen I: delivery 
prototype #1 (o). Rumen II: delivery prototype #2 
( A ) .  Rumen IV:  de l ivery prototype #3 ( N )  
Page 
95 
96 
101 
102 
103 
104 
105 
106 
ix 
LIST OF SYMBOLS 
liter 
mi 11i1i ter 
microliter 
gram 
milligram 
microgram 
kilogram 
hour 
seconds 
centimeter 
micrometer 
nanometer 
angstroms 
micromoles 
milliequivalents 
radians 
degrees centigrade 
degrees Kelvin 
revolutions per minute 
pounds 
delivery orifice width; major axis of diffusing partiel 
radius of spherical diffusion source 
surface area 
minor axis of diffusing particle 
X  
3yi^g coefficient of sliding friction 
C concentration 
Cj^ concentration of drug at opening of device 
concentration of drug at opening of device containing 
polymeric matrix 
Cg, Cg drug concentration at h into the medium 
Cg drug solubility in fluid medium 
Cg drug solubility in polymeric matrix 
Cout concentration of overflow 
^sample concentration of sample 
Cjgg concentration loss due to degradation 
CV coefficient of variation 
AC concentration difference 
D diffusion coefficient of drug in fluid medium 
D' diffusion coefficient of drug in polymeric matrix 
diffusion of species A into solvent B 
6 velocity boundary layer thickness 
6^ displacement thickness 
gg momentum thickness 
A h/5 = Sc"T/3 
e^ error 
force on particle A to give u^ 
f frictional coefficient of prolate ellipsoid 
fg frictional coefficient of sphere 
h concentration boundary layer thickness 
J release rate; joules 
xi 
k mass transfer coefficient 
K partition coefficient at polymeric matrix-fluid interface; 
Boltzmann's constant 
L length or characteristic diameter 
X diffusion path length to dissolution boundary 
M mass of drug dissolved at any time 
mass of drug dissolved but still remaining between n and X 
mass of drug released 
mass release rate 
y absolute viscosity 
Ug viscosity of pure solvent B 
n radius defining orifice width 
V kinematic viscosity = y/p 
pH acidity 
IT Pi = 3.14159 
Q volume flow rate of overflow 
Qg volume flow rate of sample 
r radius; sample correlation coefficient 
R drug transport rate away from delivery orifice 
R' drug transport rate to delivery orifice 
R" drug transport rate through polymeric matrix to delivery 
orifice 
R^ radius of diffusing particles 
Re Reynolds number 
2 
r coefficient of determination 
x i i  
p density 
s diffusion path length; standard deviation of mean 
Sc Schmidt number 
Sh Sherwood number 
t time 
e angle (degrees radians) 
USP United States Pharmacopeia 
u^ velocity of particle A 
velocity of flow in x direction 
Vy velocity of flow in y direction 
steady state fluid velocity 
V volume 
volume of overflow 
Vg volume of sample 
wt weight 
X distance in x direction 
X mean 
y distance in y direction 
dC increment of concentration 
dCdeg increment of 
dh increment of h 
ds, dA increment of diffusion path length 
dt increment of time 
dy increment of y 
dp/dx derivative of pressure with respect to x 
xi i i 
partial derivative of with respect to x 
partial derivative of with respect to y 
second partial derivative of with respect to y 
second partial derivative of with respect to x 
probability 
percent 
level of significance 
less than or equal to 
greater than or equal to 
less than 
greater than 
approaches 
complementary error function 
natural logarithm 
sine 
summation 
integral 
absolute value 
number 
hydrochloride 
nitrogen 
sodium bicarbonate 
x i v  
CaClg calcium chloride, anhydrous 
MgClg magnesium chloride 
NagHPO^ sodium phosphate, dibasic, anhydrous 
NaCl sodium chloride 
KCl potassium chloride 
NagHPO^'lZHgO sodium phosphate terahydrate 
1 
INTRODUCTION 
More than 4.5 million kilograms of antibiotics are used annually in 
today's livestock industry as feed additives to promote growth, to improve 
feed efficiency, and to provide prophylaxis. Typical administration 
levels for a number of common antibiotics used for growth promotion and 
feed efficiency in feedlot cattle are shown in Table 1. Note that the 
prescribed rates in Table 1 are constant or zero-order for the delivery 
times stated. Because of the well-defined rate profiles, administration 
of the antibiotics via a controlled release device seems appropriate. To 
develop the capability to control release of oxytetracycline HCl^ by means 
of a device governed by the Brooke and Washkuhn theory (1977) in an in 
vitro rumen is the specific purpose of this investigation. However, it is 
anticipated that controlled release device design and theory can be 
applied to other livestock-agent Interactions. 
The concept of controlled release of pharmaceuticals and other bene­
ficial agents, i.e., the delivery of a known quantity of agent at a pre­
determined rate or combination of rates to a preselected target organ 
(Bagnall, 1977), is not synonymous with slow (prolonged or sustained) re­
lease. Slow release formulations contain several times the normal single 
dose providing for replacement of the agent at some rate which gives a 
measurable increase in the length of time of activity. The rate may de­
crease due to gradual loss of agent, or increase through a maximum due to 
^Oxytetracycline HCl obtained from Pfizer Inc., 235 East 42nd 
Street, New York, NY 10017, Lot 53252-51011, 905 mcg/mg. 
2 
Table 1. Antibiotics used in feedlot cattle for feed efficiency and 
growth promotion (Trenkle, 1977) 
Antibiotic 
Recommended level 
(mg/head/day) 
Delivery time 
(days) 
Oxytetracycline HCl® 75 120 
Chlortetracycline HCl*^ 35-70 120 
Monensin^ 50-360 120 
Bacitracin 35 120 
Erythromycin Thiocyanate 37 120 
^Terramycin. 
^Aureomycin. 
^Rumensin. 
breakdown of a protective barrier (Cowsar, 1974). However, there is no 
guarantee that the rates and time periods exhibited by slow release sys­
tems are reproducible and/or optimal because, in general, they are 
sensitive to environmental conditions to which they are exposed (Baker and 
Lonsdale, 1974). In contrast, controlled release formulations may exhibit 
a fast or slow release, constant or changing release, dependent upon de­
sign. Although there may be little difference in the release profiles 
between the controlled and slow release systems, the mechanism of release 
is typically different as well as the degree of control of both the opti­
mum level and optimum time of availability of the biologically active 
agent (Cowsar, 1974). Thus, controlled release of agents is a function of 
the device design, permitting an accurate, reproducible and predictable 
administration rate and time of availability. 
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Many commercial controlled release systems have been developed in­
cluding insecticide strips, flea collars, microencapsulated pesticides, 
insecticides, and fertilizers, and medical devices for the treatment of 
glaucoma, trichoma, narcotic addiction, malaria, diabetes, cancer, and 
contraception (Cowsar, 1974; Paul, 1976). However, not all agents are 
amenable to administration by controlled release formulations, and other 
agents can be delivered with equal effectiveness by simple or more eco­
nomical alternative means. 
Attempts to use controlled release devices in the cattle industry 
have met with mixed success. Most of the commercially used controlled 
release devices have been cylindrical or spherical erodible devices im-
1 2 3 planted subcutaneously: DES implants, Synovex-S and Synovex-H im­
plants, Ralgro®'^ implants, and Relabel®^ implants. The release kinetics 
of cylindrical or spherical erodible devices are not constant or zero-
order (Hopfenberg, 1976). Matters are further complicated in that proper 
placement of the implant must be achieved for proper and reproducible 
absorption. Periodic implantation is necessary to maintain effective 
^Diethylsti1bestrol, banned from use. 
2 Estradiol benzoate and progesterone. SYNTEX Agribusiness Inc., 
Des Moines, lA. 
^Estradiol benzoate and testosterone. SYNTEX Agribusiness Inc., 
Des Moines, IA. 
^Nonhormonal anabolic agent. International Minerals and Chemical 
Corporation, Terre Haute, IN. 
^Zeranol, an anabolic agent. Brae Laboratories, Terre Haute, IN. 
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levels for extended periods of time (>100 days). Improved or 
alternative means of administration are needed. 
The tetracyclines are broad spectrum antibiotics, active against a 
wide range of gram-negative and gram-positive organisms, and are primarily 
bacteriostatic. How their growth promotion and feed efficiency effects 
are exerted in ruminants is still not well-understood. The tetracyclines 
do have at least one characteristic in common with other antibacterial 
feed additives, that being the suppression or inhibition of microorganism 
growth. In all, there may be several modes of action, the three foremost 
theories are the metabolic effect, nutrient sparing effect, and the dis­
ease control effect (Wallace, 1970). 
It has been shown that phosphorylation and oxidative enzyme reactions 
in bacteria have been inhibited by tetracycline antibiotics (Wallace, 
1970). This evidence suggests that metabolic effects account for the 
bacteriostatic or bactericidal properties of antibacterial feed additives. 
The question has not been resolved as to which enzyme systems, that of the 
host animal or those of the microflora, are involved. Since feeding 
levels are low and absorption of most additives is limited, it is doubtful 
that there is a substantial direct metabolic effect on the tissues of the 
host animal (Wallace, 1970). Thus, the indirect effects on the metabolism 
of the digestive tract microflora populations seem more logical. 
The nutrient sparing mode of action seems to be manifested through 
one or all of the following effects: 1) stimulation of microorganisms 
which favor nutrient synthesis, 2) suppression of organisms which compete 
5  
for critical nutrients, and 3) improved nutrient absorption resulting from 
thinner, healthier intestinal walls (Wallace, 1970). 
One of the major benefits of feeding chemotherapeutic compounds re­
sults in suppression or control of subclinical or nonspecific diseases 
(Wallace, 1970). Indeed, healthy disease-free animals fed in carefully 
cleaned and sterilized quarters do not respond as well to antibacterial 
additives (Wallace, 1970; Cravens and Hoick, 1970). 
In reality, metabolic effects, nutrient sparing effects, and disease 
control effects probably overlap and interrelate. It is concluded, how­
ever, that the disease control effect has the most influence on growth 
promotion and feed efficiency (Wallace, 1970). This effect contributes 
heavily in the early growth of animals, increasing their ability to sur­
vive and to perform economically. 
This investigation proposes the use of a controlled release device 
placed within the rumen to emulate the recommended levels for oxytetra­
cycline HCl of 75 mg/head/day for 120 days (Table 1). The feasibility of 
this concept will be tested by monitoring the amount of oxytetracycline 
HCl released from scaled down controlled release prototypes in artificial 
rumens. In this instance, a zero-order (constant) delivery rate is sug­
gested. It should be emphasized, however, that feedlot cattle are typi­
cally fed once or twice a day en masse resulting in a nonconstant (maybe 
even cyclic) intake of antibiotic. Since the effective constant concen­
tration of oxytetracycline HCl (or any other feed additive) within the 
rumen of feedlot cattle has not been defined for adequate growth promo-
6 
tionj the potential exists for reducing the administration levels in situ 
with the controlled release device compared with the levels prescribed 
orally. This result would presumably promise the same antibiotic coverage 
for growth promotion and feed efficiency with an increased economic bene­
fit for the livestock producer. 
^ Dr. Milton J. Allison, NADC, Ames, lA. Personal communication, 
1980. 
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LITERATURE REVIEW 
Some of the common methods for controlled release of agents are: 
1) erodible devices, 2) membrane bounded devices, 3) matrix devices, and 
4) osmotic pumps. Table 2 indicates principal references which can be 
consulted for further information on the various methods mentioned above. 
To summarize, matrix devices, erodible cylinders and spheres utiliz­
ing uniform drug loading do not offer zero-order release kinetics and 
therefore are not suitable for administering oxytetracycline HCl as speci­
fied in Table 1. Erodible slab configurations in theory give zero-order 
release but in practice are prone to difficulties due to the dependency of 
the dissolution process on environmental factors, i.e., agitation. Mem­
brane encapsulated systems offer zero-order release but because of mem­
brane physical limitations, the optimum release rate is constrained to 
7 2 
approximately 200 yg/cm -hr or 4.8 mg/cm -day (Baker and Lonsdale, 1974). 
2 This means that at best a delivery surface area of approximately 16 cm 
would be necessary for a release rate of 75 mg/day, which is reasonable 
for the proposed application in cattle. But because of the combination of 
high release rate and long delivery time, the concentration gradient 
across the membrane necessary for zero-order release (Baker et al., 1977) 
would be difficult to maintain. Osmotic pumps do not offer the magnitude 
or duration of zero-order release necessary. Current commercial models 
deliver substances up to 1 yl/hr for 170 hours (Capozza et al., 1977). 
Thus,a device recently proposed by Brooke and Washkuhn (1977) will be 
investigated for its potential as a zero-order delivery device for the 
administration of oxytetracycline HCl in the rumen. The principle 
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Table 2. Common methods for controlled release of agents and references 
Method References 
Erodible slabs, cylinders, and 
spheres 
Membrane encapsulated systems 
Matrix devices 
Osmotic pumps 
Hopfenberg, 1976 
Heller et al., 1978 
Heller, 1980 
Crank and Park, 1968 
Baker and Lonsdale, 1974 
Flynn et al., 1974 
Crank, 1975 
Theeuwes et al., 1976 
Leeper and Michaels, 1976 
Baker et al., 1977 
Higuchi, 1961 
Higuchi, 1963 
Lapidus and Lordi, 1966 
Singh et al., 1967a 
Singh et al., 1967b 
Lapidus and Lordi, 1968 
Roseman and Higuchi, 1970 
Baker and Lonsdale, 1974 
Chien et al., 1975 
Fu et al., 1976 
Paul and McSpadden, 1976 
Cobby, 1978 
Langer and Folkman, 1978 
Kaetsu et al., 1980 
Theeuwes and Higuchi, 1974 
Theeuwes, 1975 
Capozza et al., 1977 
Theeuwes and Yum, 1977 
Theeuwes and Ayer, 1977a 
Theeuwes and Ayer, 1977b 
Zaffaroni et al., 1977 
Theeuwes and Ayer, 1977c 
Capozza, 1978 
Theeuwes and Ayer, 1978 
Zaffaroni et al., 1978 
Zaffaroni et al., 1979 
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involves a particular constant geometrical relationship 
between the drug diffusion path and the effective diffusion boundary area. 
The rigid device can be charged with a drug pellet or suspension of drug 
within an aqueous gel, a waxy matrix, or a polymeric matrix. 
Figure 1 shows a cross section of the drug delivery system. It can 
be considered as a portion of a right cylinder of length L. The device in 
Figure la is charged with a solid pellet of drug which dissolves iso-
tropical ly. It is assumed that diffusion of drug out of the device is the 
rate controlling process. From Figure la, A = 20A (0 in radians). Hence, 
the relationship between the area of the dissolving drug, AL, and the 
diffusion path length, X, is a constant. 
By assuming that the rate of the transport of drug to the orifice is 
equal to the rate of transport into the surrounding fluid, the release 
rate of the drug into the external fluid can be derived. The rate of 
transport of drug to the orifice, R', is (Brooke and Washkuhn, 1977): 
R' = ^ (Cg - C^) = 2D6L(Cg - C(^) (1) 
and the rate of transport away from the orifice, R, is: 
R = T - Cg) (2) 
where = solubility of drug in the fluid 
C|^ = concentration of drug at the opening 
Cg = concentration of drug at some distance h into the fluid 
D = diffusion coefficient for drug in fluid 
By assuming = 0, and equating Equations 1 and 2 
10 
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Figure 1. Cross section of a zero-order device charged with: a. solid 
drug; b. polymeric matrix containing suspended drug (Brooke 
and Washkuhn, 1977) 
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2DaL8Cg DLCg 
( 3 )  
a + 28h 
20 
If h is constant, then the release of drug occurs at a constant rate 
during steady state. 
Figure lb shows a device filled with a suspension of drug within a 
polymeric matrix. The assumptions of Roseman and Higuchi (1970) are 
applied to this situation. They are: 1) a steady state exists, 2) the 
concentration of the drug in the matrix is much greater than its solu­
bility in the matrix, 3) the diffusion coefficients are constant, 4) dif­
fusion is the rate controlling step, rather than dissolution, and 5) the 
diffusional process occurs through the matrix phase rather than through 
pores or channels within the matrix. Since A = 20À, the relationship be­
tween the area of dissolution boundary, AL, and the diffusion path 
length, X, is a constant. 
The rate of transport of drug to the orifice is given by: 
where D' = diffusion coefficient for drug in the matrix. By assuming a 
partition of drug at the matrix-fluid interface, defined by K: 
the rate of drug release upon combining Equations 2,4, and 5 yields 
(Brooke and Washkuhn, 1977): 
DLCs 
^ " Ih/a) + (D/D'K)(l/20) (G) 
Equations 3 and 6 are derived for an ideal case where the orifice is 
infinitely small, i.e., a 0 but presents no barrier to the diffusion of 
R" = (C^ - C^) = 2D'6L(C^ - C^) (4) 
K = C^/Cb = c;/c, (5) 
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the drug. In the real case, zero-order release does not develop until the 
diffusion path length, X, becomes significantly larger than the orifice 
width, a. Thus, when the orifice width, a, has a small but real value, 
and X ^ 0, the planar model of Roseman and Higuchi (1970) is approximated. 
Therefore, the rate of drug release is initially higher than that of the 
zero-order, steady state phase. 
Brooke and Washkuhn (1977) tested the theory of their device experi­
mentally by following the amount of stearic acid released from the device 
into alcohol USP. Their device was fabricated from 18-gauge stainless 
steel with all joints silver soldered. Two entry ports were provided. 
Their prism-shaped device dimensions were 6.4 cm in length, 2.54 cm wide 
at the base, and 1.6 cm high from the base to the slot. The slot width, 
a, was 0.08 cm; the effective slot length, L, was 5.75 cm; and the angle, 
20, was 80°. Molten stearic acid was added through an entry port and 
allowed to solidify. The device held approximately 9.5 g of stearic acid. 
Upon testing, the device delivered 5.07 g of stearic acid for over 400 
hours corresponding to a delivery rate of approximately 305 mg/day for 17 
days. They further postulated that their device would, under ideal condi­
tions, release 8 g at a zero-order rate for approximately 26 days. How­
ever, their experimental trials were terminated before 8 g were released 
when irregularities on the surface of the stearic acid fill became ob­
vious. 
Brooke and Washkuhn (1977) indicated that a number of problems in 
filling the device may occur, thus influencing the zero-order release 
rates. Problems included the trapping of air bubbles in the melted 
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stearic acid and a slight shrinkage of the melt in cooling. In theory, 
there must be no penetration of fluid between the cavity wall and the fill 
to allow zero-order release rates. In addition, the theory requires the O 
transport of solid within the cavity be diffusion controlled. Thus, if 
any currents arise in the fluid within the device, deviations from the 
theory could occur. However, this should not be a source of error in the 
case of a cavity filled with a polymeric matrix. No experimental data 
were obtained for devices filled with a suspension of drug within a 
polymeric matrix by Brooke and Washkuhn (1977). 
The device proposed by Brooke and Washkuhn (1977) is of direct inter­
est, with possible release periods of the order of 30 days and with higher 
release rates currently available than with membrane bounded systems. 
This system seems to offer much latitude in delivering the required 
oxytetracycline HCl dosages (Table 1) to feeder cattle for long periods 
of time (e.g., >30 days). 
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DELIVERY DEVICE THEORY AND ANALYSES 
Although the principle of the controlled release device to be stud­
ied in this investigation was originally proposed by Brooke and Washkuhn 
(1977), a more rigorous analysis of the theoretical behavior of the device 
was offered by Lipper and Higuchi (1977). The release kinetic equations 
of Lipper and Higuchi (1977) agreed well with the experimental data re­
ported by Brooke and Washkuhn (1977). Unfortunately, the deviations of 
Lipper and Higuchi (1977) contained a minor error as will be discussed 
below. This error ultimately had little effect on the analysis of Lipper 
and Higuchi (1977) because of the fortuitous choice of 0 in the Brooke and 
Washkuhn (1977) device. 
This chapter outlines the analysis of Lipper and Higuchi (1977), the 
corrected version of that analysis, and an extension of the analysis, 
assuming dissolution of the drug as the release rate governing process. 
Methods for estimating the concentration boundary layer thickness are dis­
cussed and applied to the experiment of Brooke and Washkuhn (1977). The 
release kinetic equations governing the controlled release devices used in 
this investigation are derived. 
Brooke and Washkuhn Delivery Device: Analysis 
of Lipper and Higuchi 
This section specifies the theoretical basis of the drug delivery 
device proposed by Brooke and Washkuhn (1977) as analyzed by Lipper and 
Higuchi (1977). Refer to Figure 2 for the following analysis. 
Impermeable 
Capsule 
Figure 2. Cross sectional view of the device's drug containing cavity . The case where the charge 
of solid drug is partially dissolved is illustrated 
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Let the center that defines the arc be outside the device,and let the 
opening of the device be at radius n. The dissolution area at diffusion 
path length s is then 0L(s + n), where L is the length of the drug filled 
cavity (more specifically, the length of the opening) and 6 is in radians. 
The flow, J, at s is: 
J = 0LD(s + n)dC/ds (7) 
where D is the drug diffusion coefficient in the dissolution medium. 
Integration of Equation 7, assuming J and D constant, yields: 
J  ^ 0 ^  d C  
or 
where = drug concentration at the dissolution area 
= drug solubility in the dissolution medium 
= drug concentration at the opening 
Diffusion from the opening into the bulk, assuming a planar case, can 
be described by: 
J = -eLnDdC/dh (9) 
or, upon integration, assuming J and D constant: 
J Sq dh = -0LnD ^ dC 
or 
^ ^ e L D n C C ^  ( , 0 )  
where C q = drug concentration at a distance h into the bulk 
= 0, if sink conditions are assumed 
h = concentration boundary layer in the bulk medium. 
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Note that h is taken from to the center of the arc described by n at the 
opening. Also, note that the area for diffusion is taken as the arcuate 
surface area defined by n, not the physical opening area which is defined 
as 2nL(sin 0/2). Equation 10 is only justified if h is much less than the 
arc length at the opening (or opening width). 
Solving Equation 10 for C^, assuming C q = 0, and substituting into 
Equation 8, yields the rate of drug release as: 
GLDCc 
^ " h/n + In Vn 
Given p = drug density, the mass of drug dissolved at any time, M, 
is: 
M = p(8Lx2/2 - 0Ln^/2) 
- p6L(A - n )/2 (12) 
Solving for X  in Equation 12, substituting into Equation 11 and inte­
grating, yields a relationship between mass dissolved and time: 
2 
(h/n - 1/2)M + (M/2 + ^|^)ln(-^— + 1) 
èlDC ^ (13) 
S 
Let it be assumed that the mass of drug in solution in the diffusion 
layer is negligible compared to the total drug mass, then: 
My. = M - (14) 
where = drug mass released 
= drug mass dissolved but still remaining between n and \ 
At any given time: 
MD = / q^"" 0L(S + n)Cds (15) 
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where from Equation 7: C = ln(^ ^ ") + C^. Substituting for C in 
Equation 15, integrating, Equation 14 becomes: 
L8Cg eiC^n^ 
(peL - GLCg + 2(h/n + In X/n)) " 2(h/n + in X/n) 
( 1 6 )  
Upon substituting Equation 12 into Equation 13, yields: 
t = (h/n - 1/2)- n^)p + pX^/2 In X^/n^ 
2DCs (17) 
Equations 16 and 17 relate mass of drug released versus time for 
values of X. 
The following assumptions were used in the above analysis: 1) dis­
solution takes place isotropically, 2) mass transfer of the drug out of 
the device is the rate-determining process, not dissolution, and 3) steady 
state exists. 
Corrected analysis 
As noted above, Lipper and Higuchi (1977) used the arcuate surface 
area for defining the diffusion from the opening in lieu of the physical 
opening area, 2nL(sin 0/2). Also, h is taken as shown in Figure 2. Using 
the physical opening area in describing the diffusion from the opening 
into the bulk, assuming a planar case, Equation 9 becomes: 
J = -2nLD(sin 9/2)dC/dh (9a) 
or, upon integration, assuming J and D constant: 
Deviations from the Analysis of Lipper and Higuchi 
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J /n dh = -2n LD(sin 0/2)/^° dC 
U I'b 
or 
2n LD(sin 6/2)(C. - C^) 
J = ^ (10a) 
Equation 11 then becomes, assuming = 0; 
GLDCg 
he/(2n sin 0/2) + In X/n 
For the radial case for diffusion from the opening. Equation 11 
becomes, assuming Cq = 0: 
6LDC 
Equations 16 and 17 become, assuming a planar case: 
^ - «''s ' . ,n vn)' 
0LC 
In X/n (16a) 
2(2n(sin^0/2) 
2DC, (17a) 
For the radial diffusion case, Equations 16 and 17 become: 
.2 2 L0C 
= -T- - «LC, . . in X/n)' 
2 6LC.n' 
In X/n (16b) 
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, _ f®îi¥W)- + (^2/2 m jf/rf 
t 2DC ^ ' 
s 
Dissolution controlled mass transfer 
If the environment is infinitely well-stirred, currents probably rise 
within the device's impermeable capsule, and so the assumption that the 
release rate is diffusion controlled should be relaxed. Thus, the release 
kinetics are dissolution controlled. 
The release rate of the Brooke and Washkuhn (1977) device is then 
governed by the equation: 
J = KACG (18) 
assuming the concentration in the dissolution medium is zero. A is the 
surface area for dissolution, is the solubility of the dissolving solid 
in the dissolution medium, and k = D/h, where D is the diffusion coeffi­
cient of the solute in the solvent, and h is the thickness of the diffu­
sion layer. Equation 18 can be stated, using A = 0LA (Figure 2) as: 
0LXDC^ 
J = —^ (19) 
Equations 16 and 17, the mass of drug released and time equa­
tions, respectively, become: 
M = P9'-(A^^- n^) (20) 
t = ") (21) 
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Determination of the Concentration Boundary Layer 
In the preceding analyses, no attempt was made to quantify the con­
centration boundary layer, h. Even in the analysis of the Brooke and 
Washkuhn (1977) data by Lipper and Higuchi (1977), h was chosen to fit the 
experimental data. Since the concentration boundary layer, which is de­
pendent upon environmental conditions, influences the release kinetics of 
a device in a given situation, it is necessary to be able to quantitative­
ly estimate this parameter. This allows the investigator to judge how a 
device will function in different environmental situations. The following 
discussion outlines methods for determining a value for the concentration 
boundary layer, h. 
In many situations, as in the Brooke and Washkuhn (1977) experiments, 
mass transfer occurs by diffusion and forced convection. Because exact 
solutions of this type of problem are almost never feasible, it is conven­
ient to resort to the concept of a mass transfer coefficient, k, as fol­
lows (Seagrave, 1971): 
J = AkAC (22) 
where J is the overall mass transfer rate, A is the area for mass trans­
fer, and for transfer across a dilute film of thickness, h: 
k = D/h (23) 
where D is the diffusion coefficient of the drug in the medium. There­
fore, Equation lOa could just as well have been written as J = 
2nLk(sin 0/2)(C|^ -  C q). The problem arises on how to estimate the film 
thickness (concentration boundary layer), h, thus, defining k, with D 
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known. One might expect h to be dependent upon the convective fluid 
velocity (stirring rate) and the fluid properties. 
A flat plate in a fluid flow at zero incidence will develop a bounda­
ry layer governed by Prandtl's boundary layer theory discussed 
by H. Blasius (Schlichting, 1979). Figure 3 shows such an occurrence. 
The boundary layer equations, for steady flow in two dimensions, are: 
av^/ax + BVy/Sy =0 (24) 
(25, 
Assume that the velocity of flow is constant, and, therefore, dp/dx 5 0. 
2 2 9Vv Also, neglect 9 V^/3x as it is small in comparison with Then, 
Equation 25 reduces to: 
'"x (%) 
where v = kinematic viscosity = uid^density^~ w/P' The boundary 
conditions are 
y = 0: = Vy = 0; y = <»; 
Assuming similar velocity profiles at varying distances from the leading 
edge. Equations 24 and 26 can be solved (Schlichting, 1979) to obtain 
the velocity profile of the boundary layer. 
The velocity boundary layer thickness can be estimated as a function 
of distance along the flat plate to within 1% if we let = .99 V^, then 
(Schlichting, 1979): 
<S(x) ~ 5.0 (27) 
h(x) 
c(y) vjy) y 
Flat Plate 
Figure 3. Velocity and concentration profiles due to flow past a soluble flat plate at zero 
incidence. The velocity boundary layer (ô(x)) and concentration boundary layer ( h(x)) 
are shown 
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or over the length of the plate, L: 
f = 5.0 \f^= 5.0(Re)"T/2 (28) 
"oo*-
where Re is the Reynolds number. It is generally impossible to indicate a 
boundary layer thickness in an unambiguous way, as the influence of vis­
cosity in the boundary layer decreases asymptotically outwards. 
Perhaps a more physically meaningful measure of boundary layer thick­
ness is the displacement thickness, 6^ which is the distance by which the 
external potential field of flow is displaced outwards as a consequence of 
the decrease in velocity in the boundary layer. So for 6.| : 
^1 " -^ 0 
or from Schlichting (1979): 
6 ^ ( x )  =  1 . 7 2 0 8  ( 2 9 )  
and over the length of the plate, L: 
^1= 1.7208(Re)"T/2 (30) 
The momentum thickness, ôg» which is the loss of momentum in the 
boundary layer as compared to the potential flow is: 
V V 
Ggfx) - fQ (1 - dy 
CO 00 
or from Schlichting (1979): 
dgfx) = 0.664 (31) 
CO 
and over the length of the plate, L: 
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•^ = 0.664(Re)"^/^ (32) 
Equations 28, 30, and 32 are only valid for laminar flows, i.e., 
Re £ 3.2 X 10^ (Schlichting, 1979). For turbulent flows, i.e.. Re >3. 
X 10^, Equations 28, 30, and 32 become (Schlichting, 1979): 
0.37(Re)-T/S (33) 
^ = 0.046(RE)"^/^ (34) 
0.036(RE)"T/5 (35) 
For diffusion from a soluble flat plate (Figure 3) in an isothermal 
laminar flow at zero incidence, a concentration boundary thickness, can be 
defined as (Bird et al., 1960): 
C, - C 
h(x) = r / (1 - r  _  r )  dy (36) 
" V ^0 
Alternatively, we can correlate h with 6, the velocity boundary layer, as 
A = h/6. For A £ 1, then (Bird et al., 1960): 
A = Sc-1/3 = 5" (37) 
0 
where Sc = y/pD = v/D = Schmidt number. Thus, h can be estimated knowing 
6 and Sc. 
Another method to estimate k in Equation 22, and thus h, is to use 
typical correlations specified for forced convection around objects 
(Seagrave, 1971). For forced convective mass transfer around a cylinder: 
Sh = (0.35 + 0.56 Re1/2)Sc°'3 (38) 
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where Sh = Sherwood number = kL/D 
Re = Reynolds number = LV^v 
Sc = Schmidt number = v/D 
L = characteristic diameter 
D = diffusion coefficient 
V = kinematic viscosity = y/p 
= steady state fluid velocity 
For forced convective mass transfer around a sphere: 
Sh = 2.0 + 0.60 ReT/2sc0'33 (39) 
Thus, k is estimated from either Equations 38 or 39 and is dependent 
upon qeometry and h as determined from Equation 23. 
Analysis of Brooke and Washkuhn Experimental Data 
Brooke and Washkuhn (1977) tested the theory of their device experi­
mentally by following the amount of stearic acid released from the device 
into alcohol USP. A temperature of 30°C was maintained. The contents of 
the alcohol-device containing beaker was stirred at 50 rpm by a 2 cm 
radius propeller. The release of stearic acid versus time was followed 
for three trials with a mean release rate of 12.72 mg/hr (Brooke and 
Washkuhn, 1977). It is important to note that Brooke and Washkuhn (1977) 
did not correlate their experimental results with their theory. Lipper 
and Higuchi (1977) used the mass released versus time Equations 16 and 17 
to generate data to simulate the case experimentally tested by Brooke 
and Washkuhn (1977). Table 3 shows parameters used by Brooke and Washkuhn 
(1977), those derived by Lipper and Higuchi (1977) using Equations 16 
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Table 3. Brooke and Washkuhn (1977) delivery device parameters, Lipper 
and Higuchi (1977) parameters, and parameters derived in mass 
transfer coefficient, k, analysis 
h 
(ym) 
n 
(ym) 
0 
(rad) 
L 
(cm) 3 (g/cm ) 
P 
(g/cm^) 
D 
2 (cm /sec) 
Brooke & 
Washkuhn 622* 1.4 5.75 
Lipper & 
Higuchi 100 540 1.4 5.75 0.048^ O.94C 2.65xlO"5 
present 
analysis 122^ 622® 1.3963 5.75 0.045® 0.9408^ 2.65x10"^ 
^Derived from a = 2n sin 0/2 = 0.08 cm (Brooke and Washkuhn, 1977). 
'^From Stecher, 1968, p. 980. 
^From Weast, 1974, p. C-396. 
^Estimated from Equation 38. 
®At 30°C from Stephen and Stephen, 1963. 
and 17, and those parameters used in the present analysis which quanti­
tatively estimate a value for h, 
Brooke and Washkuhn (1977) graphed mass of stearic acid released 
versus time for their three experimental trials. Using a linear regres­
sion analysis on all data, the following equation was used to summarize 
the release profile: = 12.72t - 21.9 with r^ = 0.985. This indicates 
a release rate of 12.72 mg/hr over the time period tested. 
Lipper and Higuchi (1977) used Equations 16 and 17 to generate 
data to simulate the experimental case of Brooke and Washkuhn (1977). 
They used the parameters in Table 3. The diffusion coefficient was deter­
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mined by forcing the Equations 16 and 17 to yield the point = 
5.07 g at t = 400 hr. This led to a value of D = 2.65 x 10"^ cm^/sec. To 
yield the point = 5.07 g at t = 400 hr, then X = 1.185 cm. Using this 
value for X in Equation 11, then at steady state, J = 11.26 mg/hr. 
The present analysis assumes that the concentration boundary layer, 
h, can be estimated from knowledge of the environment. Also, n is rede­
fined correctly by determining it from the opening width, 2n(sin 6/2). The 
O 
kinematic viscosity of ethanol at 30°C was determined as 1.2843 x 10" 
2 cm /sec. The characteristic diameter of the device, L, was estimated as 
the diameter of a cylinder with the same volume. Thus, L = 1.6085 cm. 
The maximum velocity, V^, was estimated as = 2nr(rpm) = 2n(2 cm) 
(50 rpm) = 10.472 cm/sec. Thus, Re = 1311.53, which implies laminar flow. 
p 
Using Equation 38 with Equation 23, and D = 2.65 x 10 cm /sec, h = 
122 ym. Therefore, from Equations 11, 16, and 17 with X = 1.185 cm 
and the other parameters in Table 3: = 5.075 g at t = 407 hr, J = 
10.97 mg/hr at steady state. Using the more valid approach of Equations 
11a, 16a, and 17a; = 5.077 g at t = 390 hr, J = 11.36 mg/hr at 
steady state. 
From the above analysis, it seems that the concentration boundary 
layer, h, can be estimated successfully as applied to the experiment of 
Brooke and Washkuhn (1977). 
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Current Delivery Device Theory 
This section specifies the theoretical basis of the delivery device 
used in this investigation. Refer to Figure 4 for the following analysis. 
Let the center that defines the arc be at the opening of the device 
and let the opening be described by n, as 2n. The dissolution area at 
diffusion path length s is then 0L(s + n), where L is the length of the 
drug filled cavity (more specifically, the length of the opening) and 0 = 
w radians. For other values of 8, Equations 11a, 16a, and 17a should be 
used for the planar case for diffusion from the opening. Equations lib, 
16b, and 17b should be used for the radial case for diffusion from the 
opening. The flow, J, at s is: 
J = 0LD(s + n)dC/d(s + n) (7a) 
where D is the drug diffusion coefficient in the dissolution medium. 
Integration of Equation 7a, assuming J and D constant and the cavity 
filled to the opening, yields: 
or 
J .  (40) 
where = drug concentration at the dissolution area 
= drug solubility in the dissolution medium 
Cjj = drug concentration at the opening 
Diffusion from the opening, 2n, into the bulk, assuming a planar 
case, can be described by: 
Solid 
Drug 
Impermeable 
Capsule 
Fluid 
Figure 4. Cross sectional view of the device used in the current investigation. The charge of solid 
drug is partially dissolved 
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J = -2nLD dC/dh (41) 
or, upon integration, assuming J and D constant: 
J /q^ dh = -2nLD dC 
or 
2nLD(C. - C q) 
where C q = drug concentration at a distance h into the bulk 
= 0, if sink conditions are assumed 
(42) 
h = diffusion boundary layer in the bulk medium 
Again, Equation 42 is only justified if h is much less than the opening 
width. 
Solving Equation 42 for C^, assuming Cq = 0, and substituting into 
Equation 40, yields the rate of drug release as: 
If we assume a radial case for diffusion from the opening, 2n, into 
the bulk, then Equation 42 becomes: 
This analysis assumes a hollow cylinder described by n < r < h, with the 
surface r = n maintained at a constant C^^. This is justified if h/n is 
very large and the bulk medium is stagnant. 
Solving Equation 44 for C^, assuming Cq = 0, and substituting into 
Equation 40, yields the rate of drug release as: 
J = 
6LDC, (43) 
he/2n + In ^  
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eLDC. 
•' ° eln h/n , X (43a) 
-ST- n 
Given p = drug density, the mass of drug dissolved at any time, M, is: 
M = p0LX^/2 (45) 
Solving for A in Equation 45, substituting into Equation 43 and inte­
grating, yields a relationship between mass dissolved and time: 
(0h/2n - 1/2)M + ^ ln(^^) 
p0Ln^ 
t = 8LDC (46) 
s 
Let it be assumed that the mass of drug in solution in the diffusion 
layer is negligible compared to the total drug mass, then: 
= M - (14) 
where = drug mass released 
= drug mass dissolved but still remaining between 0 < s + n < A 
At any given time: 
0L(s + n)Cd(s + n) (47) 
where from Equation 7a; C = (J/0LD)ln((s + n)/X) + C^. 
Substituting for C in Equation 47, integrating, Equation 14 becomes: 
"r ° V (PGL - eLCj + eh ^ x.) (48) 
2(2^ + In n' 
Upon substituting Equation 45 into Equation 46, yields: 
p,2(e^ . 1) , in 4 
t ' IDC; (49) 
Equations 48 and 49 relate mass of drug released versus time for 
33 
values of À. 
It can be shown that for a radial case for diffusion from the opening 
into the bulk medium, that Equations 48 and 49 become: 
-2 8LC, 
"r ' T - 8LCs + 0in h/n ^ , *,> 
2(—jji 1" n' 
^^2(6!^ - Tj + In A! 
t = 2DC; — <^Sa) 
The following assumptions were used in the above analyses: 1) dis­
solution takes place isotropically, 2) mass transfer of the drug out of 
the device is the rate-determining process, not dissolution, and 3) steady 
state exists. 
Figure 5 shows the behavior of release rate (Equation 43) as a 
function of X using three sets of reasonable values of h/n, assuming n = 
.01 cm. It is apparent from Figure 5 that in all cases the release rate 
from the controlled release device is not strictly zero-order. Initially, 
the release rates are high, settling down to release rates approximating 
zero-order. 
The family of curves in Figure 5 clearly demonstrates the effect of 
the concentration boundary layer thickness, h. As h increases with con­
stant n, the resulting release rate is attenuated and also the release 
rate profile is flatter, approaching zero-order more closely. Alterna­
tively, if n decreases with h constant, as with clogging of the delivery 
orifice, the release rate is also attenuated, the profile approaching 
zero-order more closely. It is advantageous to choose a large 0 in the 
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3 
2 
T 
0 
Xi cm 
Figure 5. Release rate as a function of X .  
assuming n = 0.01 cm, are: h/n = 
•h/n = 2.5 (A) for 6 = U radians 
The values used for h/n, 
0.2 (o), h/n = 1.0 (A), and 
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controlled release device to minimize the initial high release rates and 
maximize the long term release rates. However, a small 9 is advantageous 
in minimizing changes in release rate due to changes in h/n. 
If the release kinetics are dissolution controlled, then the release 
rate of the device (Figure 4) is governed by Equation 19. The mass of 
drug released and time equations, respectively, become: 
M = (50) 
t = ^ (51) 
Summary 
The analysis of Lipper and Higuchi (1977) is in error by defining 
mass transfer from the arcuate surface area at the opening. Mass transfer 
from the device is more appropriately described as being from the opening 
surface area, 2nL(sin 9/2). When 9 is small, 8 < ÏÏ/2 radians, there is 
little discrepancy between Equations 11 and 11a. However, when 9 -» w 
radians, the h9/(2n sin 9/2) term in Equation 11a is approximately 57% 
greater than the h/n term in Equation 11. Thus, Equations 11a, 16a, and 
17a describe the release kinetics of the Brooke and Washkuhn (1977) 
device from 0 < 9 < it radians more adequately than Equations 11, 16, 
and 17. 
The radial case for diffusion. Equations lib, 16b, 17b, 43a, 48a, 
and 49a, is presented for completeness. In a stirred environment, 
this approach is not valid as the radial case theory is dependent upon 
a stagnant bulk medium. 
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Release kinetics when the device is dissolution controlled, Equations 
19, 20, 21, 50, and 51, are presented as an indication of what may be 
anticipated as the upper limit for release rate. Because of the 
experimental setup involved in the Brooke and Washkuhn (1977) experiment 
and current investigations, these equations are not useful in the analysis 
of the experimental data. 
Two methods for estimating the concentration boundary layer, h, are 
presented. These are flat plate boundary layer theory. Equation 37, and 
forced convection around objects using similitude. Equations 38 and 39. 
No one method is universal. The concentration boundary layer estimated 
from Equation 38 seems to apply to the in vitro experiment of Brooke 
and Washkuhn (1977) as indicated by the closeness of the values obtain­
ed for the release rate by Lipper and Higuchi (1977) and the analysis 
using Equations 11a, 16a, and 17a. 
Equations 43, 48, and 49 govern the release kinetics of the 
delivery device used in this investigation. The effects of h and n 
are shown in Figure 5. Figure 5 indicates that in theory the controlled 
release device used in this investigation is not strictly zero-order. 
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EXPERIMENTAL PROCEDURES 
This chapter describes the various apparatuses, techniques, and 
methods utilized to monitor and analyze the release of oxytetracycline HCl 
from the controlled release devices. Artificial rumens were fabricated 
based on successful designs reported in the literature. Methods for esti­
mating the necessary physical parameters (diffusion coefficient, drug 
solubility) for device design are described. A fluorometric means of 
measuring oxytetracycline HCl concentration is outlined. Compression of 
the powdered drug into solid form and its bulk density measurement are 
described. The controlled release device fabrication procedure and a 
mathematical means of estimating the release kinetics within the artifi­
cial rumens are discussed. 
Artificial Rumen Fabrication 
A variety of in vitro systems for the study of rumen microorganisms 
and emulation of rumen conditions have been designed (Adler et al., 1958; 
Stewart et al., 1961; Harbers and Tillman, 1962; Fina et al., 1962; 
Rufener et al., 1963; Slyter et al., 1964; Aafjes and Nijhof, 1967; Abe 
and Kumeno, 1973; Slyter, 1975; Hoover et al., 1976a; Hoover et al., 
1976b; Czerkawski, 1976; Czerkawski and Breckenridge, 1977). Some of the 
criteria for successful design and operation of an artificial rumen are 
temperature control, redox potential control (very low), replication, ease 
of measurement, stability of pH, production of volatile fatty acids, 
efficiency of stirring, removal of waste products, and measuring gaseous 
exchanges. 
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The artificial rumen was constructed from a 200 ml Pyrex culture 
flask J The flask was jacketed, providing for temperature control, and 
contained an overflow tube. A #13 rubber stopper was used to cap the 
large opening at the top through which provisions were made for infusing 
an artificial saliva solution (McDougall, 1948; see Appendix), sampling of 
rumen contents, and either gaseous sampling or gaseous flushing of the 
system. A simple gas check valve was inserted through the rubber stopper 
to help alleviate internal pressure due to gas accumulation. The artifi­
cial rumen was stirred via a magnetic stirring plate and 1.5 inch stirring 
bar at approximately 200 rpm. Temperature control of the artificial rumen 
2 
was accomplished by pumping water through the jacket of the flask from a 
large water bath maintained at 38.3°C. Any overflow was allowed to flow 
(by gravity) into a 1 liter beaker, the end of the overflow tube being 
submerged at all times (initially in water). Figures 6 and 7 show the 
system during operation. 
Upon inoculation with rumen contents from a fistulated heifer, the 
artificial rumen was flushed for one minute with 100% Ng gas to initially 
approximate anaerobic conditions. The artificial saliva solution 
(McDougall, 1948; see Appendix) was infused using a peristaltic pump at 
a rate of 300-400 ml/day to obtain a 1.5-2.0 turnover rate. The apparatus 
^Wheaton Scientific, Mill vil le, NJ, #07786. 
^Bronwill® Thermomix 1440, VWR Scientific, San Francisco, CA. 
^Mini puis II, Gil son Medical Electronics, Inc., Middleton, WI. 
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Figure 6. Photograph of in vitro rumen showing internal contents. Stirred 
contents (A), gas bubbles (B), and food cap (C) are shown 
Figure 7. Photograph of six in vitro rumens in operation showing general 
overall setup 
was fed once daily with 3.2 g dehydrated alfalfa^ and 2.0 g grain mix-
ture. This was accomplished by removing the rubber stopper, pouring in 
3 the ground feed, replacing the stopper, then flushing the artificial 
rumen 2-3 seconds with 100% Ng gas. 
The viability of the artificial rumen was established by monitoring 
the pH^ and volatile fatty acid concentrations (Lambert and Moss, 1972). 
Four artificial rumens were studied: 1) rumen I: delivery prototype #1, 
2) rumen II: delivery prototype #2, 3) rumen III: control, and 4) rumen 
IV: delivery prototype #3. Samples were taken of the original inocula­
tion from the fistulated heifer, the pH and the volatile fatty acid com­
position were determined. The pH of each artificial rumen was determined 
from samples taken for oxytetracycline HCl concentration measurement. 
Samples for volatile fatty acid concentrations were taken approximately 
every week, and then were frozen until subsequent analysis. All samples 
for pH and volatile fatty acid production were taken at the same time 
after feeding (7 hours). The artificial rumens were allowed to ferment 
eight days before the delivery prototypes were introduced into the 
^Merry Mixer, Consolidated Blenders, Inc., Fremont, NE. 17% de­
hydrated alfalfa; crude protein, not less than 17.0%; crude fat, not less 
than 1.5%; crude fiber, not more than 27.0%. 
p 
Ralston Purina Co., Iowa Falls, lA. 59.9% ground or cracked corn, 
15.8% whole oats, 10.0% 44% soybean meal, 10.0% dried molasses, 2.5% soy­
bean meal and corn to provide same nutrient level as 50 lbs linseed meal, 
1.0% trace mineral salt, i.5% dicalcium phosphate, 0.1% vitamins A and D 
to provide 12,000,000 units vitamin A/ton feed and 6,000,000 units 
vitamin D/ton feed. 
Food Chopper No. 2, Universal Chopper Division, Union Manufacturing 
Co., Meriden, CT. 
^Model 10, Corning Scientific Instruments, Medfield, MA. 
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artificial rumens. Thus, pH and volatile fatty acid data were obtained 
for 92 days and oxytetracycline HCl release from the delivery prototypes 
was observed for 84 days. 
Measurement of Oxytetracycline HCl Concentrations 
Methods for quantitative determination of tetracycline antibiotics 
have been established (Kohn, 1961; Ibsen et al., 1963; Hayes and DuBuy, 
1964; Poiger and Schlatter, 1976). Each technique utilizes a spectro-
photofluorometer, but differs in extraction method. The method of Poiger 
and Schlatter (1976) for serum, which is based on the solvent extraction 
of mixed tetracycline-calcium trichloroacetate ion pairs from aqueous 
solutions, was used in this investigation. 
A known amount (by weight) of oxytetracycline HCl was dissolved into 
a known volume of rumen fluid to obtain a concentration of 1 mg/ml. The 
rumen fluid was from an artificial rumen which had been fermenting for 
over 4 weeks. Serial dilutions of the 1 mg/ml solution into the same 
rumen fluid were performed to obtain dilutions of 100, 50, 25, 10 and 1 
yg/ml. These solutions were analyzed as fresh solutions. The fluores­
cence intensity of the solutions was measured on a spectrophotofluorome-
ter^ at excitation and emission wavelength settings of 400 nm and 505 nm, 
respectively. 
The concentration-fluorescence data were graphed for: 1) fresh solu­
tions with powdered oxytetracycline HCl, and 2) fresh solutions with 
^Aminco Bowman Spectrophotofluorometer, Model #4-8202, American 
Instrument Company, Inc., Silver Spring, MD. 
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compressed oxytetracycline HCl. Linear regression analyses were performed 
on the data after subtraction of the blank (zero concentration fluores­
cence reading) values. Since it was known a priori that the origin must 
lie on the regression line, the regression curves for the data were forced 
through the origin. 
Previous experiments had indicated that the 0-100 yg/ml concentration 
range was approximately linear, whereas concentrations greater than 100 
yg/ml exhibited nonlinearity due to increased absorption of the excitation 
and emission light (Beer-Lambert effect). However, since the concentra­
tions of oxytetracycline HCl in the in vitro experiments were less than 
100 yg/ml, the linear relationship between concentration and fluorescence 
intensity was used to quantify the amount of oxytetracycline HCl being 
released from the device. 
Variables affecting the fluorometer analysis of oxytetracycline HCl 
were studied. Specifically: 1) the effect of storing drug solutions at 
4°C, 2) the effect of storing drug solutions at 25°C, and 3) the effect of 
elevated temperatures (39°C) on the drug solutions. An artificial rumen 
fluid (see Appendix) was used as the solvent. The concentration-fluores­
cence data were obtained from analyses of fresh solutions of compressed 
drug in the artificial rumen fluid as described above. 
Compression of Oxytetracycline HCl: Density Measurement 
The density, p, is a necessary parameter in determining the mass of 
drug released with respect to time (Equations 48 and 49). Thus, the 
apparent bulk density was estimated. 
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Powdered oxytetracycline HCl was placed into bar dies and subjected 
to compression in a pneumatic press.^ Stearic acid was used as a lubri­
cant. The material was carefully removed from the die and stored in a 
refrigerator until use. 
The apparent bulk density of the compressed drug samples was esti­
mated by weighing the specimen in room air and dividing by the specimen 
volume, obtained from the overall dimensions of the sample used. 
In most instances where solid drug loading is indicated, the highest 
density obtainable is preferred allowing the physical parameters of the 
device to govern the release kinetics. The maximum equipment capacity 
(~2000 kg/cm ) was used. Indications of liquefaction of the oxytetra-
cycline HCl were noted at the ends of the bar specimens, The ends of the 
bar specimens, however, were not used in the drug delivery experiments,and 
the apparent bulk density was determined only for that portion of the 
solid oxytetracycline HCl bar used. 
Solubility of Oxytetracycline HCl in 
Artificial Rumen Fluid 
The solubility of oxytetracycline HCl in artificial rumen fluid (see 
Appendix) at 38.3°C was determined using the procedures in The United 
States Pharmacopeia (1980). 
Previous studies (Regna and Solomons, 1951; Weiss et al,, 1957) had 
determined the solubility of oxytetracycline and oxytetracycline HCl in 
^Carver Laboratory Press, Fred S. Carver, Inc., New York, NY. 
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water at 23°C and 28°C, respectively. At 23°C (pH 7.0), for oxytetra-
cycline, = 1.1 mg/ml (Regna and Solomons, 1951) and at 28°C, for 
oxytetracycline HCl, = 6.9 mg/ml (Weiss et al., 1957). 
Diffusion Coefficient Estimation 
From hydrodynamical theory, the diffusion coefficient of species A in 
solvent B can be estimated from the Nernst-Einstein equation (Bird et al., 
1960): 
"AB = " (52) 
where K = Boltzmann constant = 1.380622 x 10"^^ J/°K 
T = degrees Kelvin 
u^/F^ = frictional coefficient of spherical particle A = fg 
u^ = velocity of particle A 
F^ = force on particle A to give Uy^ 
With slip at the sphere-fluid interface possible, then: 
2yp ^A^AR 
•"A " ®'^VA'^A^3yg + 
where = viscosity of pure solvent 
= radius of diffusing particle 
= coefficient of sliding friction 
For large particles, the solvent molecules tend to be dragged along with 
the diffusant so F^ = Gny^u^R^, and Equation 52 becomes: 
D^g = KT/67rygR  ^ (53) 
which is the Stokes-Einstein equation. Under a "slip" condition, = 0, 
FA = 4ïïygU^Ry^ and : 
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D^g = KT/4TTygR^ (54) 
The above Equations 52, 53, and 54 were derived for spherical 
particles, t?ut are applicable to ellipsoids, For oblate and prolqte 
ellipsoids, the equations must be modified to account for the greater 
surface area and thus a greater resistance to diffusion. For a prolate 
ellipsoid, the ratio of the frictional resistance to that of a sphere of 
equal volume is (Tanford, 1961): 
X. = f = (1 - (55) 
^0 '""«'A + (1 -
where a = major axis 
b = minor axis 
f = frictional coefficient of prolate ellipsoid 
= radius of a sphere of equal volume to the ellipsoid, i.e., 
4/3 (ttR^) = 4/3{TTab^) 
It must be noted that the radius to be used in Equations 52-55 
is not that of the bare molecule but of the hydrodynamic particle. The 
hydrodynamic particle consists of the diffusant molecule plus any solvent 
or solute (such as a complexing agent) that is adsorbed or bound to the 
surface or entrapped within the diffusant. Since oxytetracycline HCl 
hydrolyzes and chelates with diatomic ions readily, the resultant volume 
increase will increase the frictional coefficient and decrease the diffu­
sion coefficient. Thus, the above estimation for D in many cases is only 
useful in predicting the appropriate order of magnitude. 
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The diffusion coefficient for oxytetracycline HCl can be predicted 
using another method (Hussain, 197?), assuming values for the surface area 
of dissolving drug and the solubility of the drug in the dissolution 
medium. The amount of drug dissolved under sink conditions as a function 
of time can be calculated from Pick's first law: 
AC Dt 
M = (56) 
where M = amount of drug dissolved in time t 
A = surface area occupied by the total weight of the sample 
= solubility of the drug in the dissolution medium 
D = diffusion coefficient 
h = thickness of the diffusional boundary layer = 50 x 10"^ cm at 
55 rpm (Hussain, 1972) 
Therefore, 
D = (57) 
An in vitro experiment was done to determine the diffusion coeffi­
cient of oxytetracycline HCl in artificial rumen fluid (see Appendix) at 
38.3°C. The concentration change in a semi-infinite medium due to diffu­
sion from a spherical source can be expressed as (Crank, 1975): 
C = erfc " ^) (58) 
zm 
where C = concentration at r 
Cg = solubility of diffusing agent in the medium 
a = radius of spherical source 
r = radial distance from source to concentration measurement point 
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t = time 
D = diffusion coefficient of agent in medium 
A particle of compressed oxytetracycline HCl was suspended in an 
unstirred volume of artificial rumen fluid. Samples from the medium were 
taken at various times. The concentration of the drug in the samples was 
determined fluorometrically as described previously. An allowance for 
degradation was included based on the data of Bohonos et al. (1953). The 
radius of the drug particle was estimated from the formula for the volume 
of a sphere. The volume of the particle was obtained from the known den­
sity and the weight of the drug particle before immersion in the fluid 
medium. 
The diffusion coefficient for oxytetracycline HCl in the artificial 
rumen fluid was determined by the following method: 
1. Plot C(t). 
2. For various diffusion coefficients, D, compute theoretical C^(t) 
using Equation 58 for times indicated by each experiment. 
3. Minimizing 2|C(t) - C^(t)|^ = Ze?, the sum of the errors squared 
for t > 0, the best D for the experimental data can be obtained. 
Delivery Device Fabrication 
Three prototypes #1-3 were fabricated simultaneously. Compressed 
oxytetracycline HCl bars (approximate dimensions: 0.557 x 0.24 x 6.0 cm) 
were embedded in cold cure dental acrylic^ (Figure 8). The dental 
^The Hygienic Dental Mfg. Co., Akron, OH. 
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3 ' , 
Figure 8. Photograph of prototypes #1-3. Scale bar = 1 cm 
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acrylic was allowed to cure for 48 hours. The delivery slot was machined 
into the dental acrylic using a 0.006 inch slotting blade (Figure 8). 
This was done deep enough to expose the solid oxytetracycline HCl core. 
After slotting, measurement of the delivery slot width gave a value of 
approximately 0.014 inch. This increase in slot width was probably due to 
wobble in the blade-arbor assembly used in the slotting process. After 
® 1 
slotting, a thin coat of Silastic sealant was applied to the outside of 
the delivery prototypes. 
Note that the application of any device within a biological system 
necessitates the use of materials that are biocompatible. An added re­
striction in this case is that the materials must be impervious to the 
environment, especially water. Both restrictions are met by the dental 
acrylic and the Silastic® sealant. 
In Vitro Model for Drug Delivery Measurement 
The experimental model used in determining the in vitro release 
kinetics of the prototype devices is shown in Figure 9. 
The rate of change of concentration within the artificial rumen, C, 
is given by the mass balance equation: 
O'out - %'san,ple " ^  " 
where V = volume of artificial rumen, 200 ml 
Qg = volume flow rate of measurement sample, 7 ml/At 
^Silastic® Medical Grade Adhesive, Silicone Type A, Dow Corning, 
Midland, MI. 
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Figure 9. Model for measuring drug release from delivery devices in the 
in vitro rumens 
C = concentration within artificial rumen 
Q = overflow flow rate due to influx of artificial saliva solution 
C: . = concentration of overflow out 
^sample ~ concentration of measurement sample 
Cjgg = concentration of drug loss due to degradation 
My, = mass release rate 
From Bohonos et al. (1953), the change in concentration due to drug 
degradation relative to the initial concentration, C, was Cjgq/C = 
0.484t. Therefore, dC^^g/dt = 0.484C. The mass balance equation becomes: 
"r = " ^  ^ ^sample 
If the in vitro rumen is well-stirred, the instantaneous measurement 
of both and C can be represented by the concentration of the instan­
taneous sample, Thus, = C = at that instant in 
time, t. Realize, however, that C is a function of time, C(t). If it is 
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assumed that C(t) varies piecewise linearly from tg < t < t^, then 
tl t-j C-tg + Ct"] 
C(t)L can be estimated by an average, C(t)L = —-5 • Assuming V 
^0 ^0 
t, C-^Q + 0^1 
and My, constant and utilizing and C(t)|^^ = g » 
integration of the mass balance equation yields: 
"t t t t 
/. 1 HI dt = VI ^ dC + 4 ^  QC(t)dt + Q C. dt + 0.484 V/. ^ C(t)dt 
to r tQ tQ us t-, tg 
or 
'to ' "t, 
N,(t, - tj) = V(C^^ - C,^) + Q( %  ' ) ( t , -  t g )  +  Q ^ C ^ ^ A t  
'to ' 't, 
+ 0.484V{—Ï-5 - TG) 
The mass of drug released from t^ < t < t-j is then: 
t 
^tg ^t, 
+ 0.484V(—y-2 ^)(t^ - tg) (59) 
where V^^ = volume of overflow from tg < t < t^ 
Vg = volume of measurement sample taken at t^ 
Thus, the mass of drug released from the delivery prototype in the 
artificial rumen from tg < t < t-j can be determined by sampling the con­
tents of the artificial rumen periodically, measuring the concentration 
of the sample, measuring the overflow volume and using Equation 59 with 
known V and V.. 
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The release rate, J, is best determined from the slope of the linear 
regression analysis of the experimental sum of mass of oxytetracycline HCl 
released versus time. However, the average release rate, J = ZM^/t, will 
also be reported. 
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RESULTS AND DISCUSSIONS 
This chapter reports the oxytetracycline HCl concentration-fluores­
cence calibration curves used to measure drug concentrations. Temperature 
effects on drug degradation are discussed. Estimations of the drug diffu­
sion coefficient and its solubility in rumen fluid are given. These 
values were ultimately used in the design of three controlled delivery 
prototypes whose oxytetracycline HCl release rates were monitored in the 
artificial rumens. The experimental release of oxytetracycline HCl from 
the three controlled release prototypes is reported and discussed. The 
viability of the artificial rumens in comparison to the in vivo system is 
discussed. 
Measurement of Oxytetracycline HCl Concentrations 
Refrigeration of the oxytetracycline HCl solutions at 4°C did not 
change the fluorescence readings appreciably over a period of 7 days. A 
1% decrease was noted for the 100 yg/ml solution. There should be no de­
tectable loss on storage at 4°C for at least 1 month (Regna and Solomons, 
1951). This indicates that samples can be stored with no significant 
loss in fluorescence intensity until the chemical techniques of Poiger 
and Schlatter (1976) can be performed. 
A 10% decrease in fluorescence intensity was noted for the 100 yg/ml 
solution after 24 hours at 25°C (pH 6.1). At pH 1.0-2.5 there should be 
no detectable loss at 25°C over periods of at least 30 days (Regna and 
Solomons, 1951). 
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The oxytetracycline HCl solutions maintained at 39°C showed sig­
nificant degradation. The half-life was determined as approximately 19 
hours. Half-lives of 26 hours (Regna and Solomons, 1951) and 21 hours 
(Bohonos et al., 1953) at 37°C (pH 7.0) have been reported for aqueous 
oxytetracycline solutions. The degradation profile was similar to that 
found by Bohonos et al. (1953). 
The oxytetracycline HCl concentration-fluorescence curve for fresh 
solutions of compressed drug in artificial rumen fluid was obtained from 
three separate trials. Table 4 summarizes the raw data and the linear 
regression analysis on the composite of all data. The regression line, 
selected data points, and the 95% confidence bounds are shown in Figure 
10. 
The oxytetracycline HCl concentration-fluorescence curve for fresh 
solutions of powdered drug in rumen fluid was determined from one trial. 
Table 5 summarizes the raw data and linear regression analysis on the 
data. Selected data points, the regression line, and the 95% confidence 
bounds are shown in Figure 11. 
The oxytetracycline HCl concentration-fluorescence curve for fresh 
solutions of compressed drug in rumen fluid was determined from three 
separate trials. The raw data and the linear regression analysis on the 
composite of all data are shown in Table 6. Selected data points, the 
regression line, and the 95% confidence bounds are shown in Figure 12. 
The concentration-fluorescence regression curve for oxytetracycline 
HCl in artificial rumen fluid (Table 4) was substantially different from 
the regression curves for oxytetracycline HCl in the rumen fluid taken 
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Table 4. Summary of raw data and regression analysis for fresh solutions 
of compressed drug in artificial rumen fluid 
Concentration (ug/ml) 
100 50 25 10 1 
Fluorescence intensity 
Trial 1 34.36 19.36 9.10 2.38 0.07 
33.66 18.49 9.25 2.62 0.00 
Trial 2 34.03 18.29 7.74 2.91 0.07 
36.13 18.77 7.46 2.92 0.04 
Trial 3 31.90 15.64 8.29 2.85 0.00 
30.70 16.36 7.57 2.95 0.01 
5.7% 8.3% 9.5% 8.2% 110.4% 
Regression analysis through origin 
Concentration = 2.95 x fluorescence intensity 
r = 0.995 
n = 30 
95% confidence bounds 
Slope: 2.83 < 2.95 < 3.05 
Intercept: -1.37 < 0 < 1.37 
^Coefficient of variation = = • 100. 
from the in vitro rumens (Tables 5 and 6). This was probably due to the 
difference in composition between the two rumen fluids. A difference in 
the concentration-fluorescence regression curves for powdered and com­
pressed oxytetracycline HCl in rumen fluid can be seen from Tables 5 and 
6. The 11% difference in the slopes of the regression curves was probably 
due to a loss of potency upon compression of the oxytetracycline HCl 
powder. 
The coefficients of variation are shown in Tables 4-6 for each con­
centration. The weighted mean coefficients of variation for the measure-
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Figure 10. Profile of the linear regression analysis for fresh solutions 
of compressed oxytetracycline HCl in artificial rumen fluid. 
The 95% confidence bounds are given as dashed lines. Selected 
points from Table 4 are shown 
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Table 5. Summary of raw data and regression analysis for fresh solutions 
of powdered drug in rumen fluid 
Concentration (yg/ml) 
100 50 25 10 1 
Fluorescence intensity 30. 78 13.68 6 .12 2.52 0.03 
26. 68 12.51 6 .02 3.48 0.64 
27. 58 13.26 7 .30 1.97 0.11 
28. 38 15.81 6 .88 2.46 0.04 
33. 78 15.75 7 .67 2.95 1.16 
27. 68 17.61 7 .38 2.57 0.00 
CV^ 9. 1% 13.1% 10 .0% 19.2% 143.2% 
Regression analysis through origin 
Concentration = 3.40 x fluorescence intensity 
r = 0.991 
n = 30 
95% confidence bounds 
Slope: 3.22 < 3.40 < 3.58 
Intercept: -1.92 < 0 < 1.92 
^Coefficient of variation = = « 100. 
ments in Tables 4-6 are: Table 4 - 28.4%, Table 5 - 38.9%, and Table 6 -
38.1%. These mean values are considerably greater than the coefficient of 
variation found for chlortetracycline in serum (6.5%, Poiger and 
Schlatter, 1976). This discrepancy is largely due to the poorer recovery 
of oxytetracycline from water (50%) compared to the recovery of chlor-
tetracycline from water (>95%) (Kohn, 1961) during extraction into the 
organic solvent before fluorimetric determination. The high coefficients 
of variation indicate that the procedure used to measure oxytetracycline 
HCl concentrations in rumen fluid was not as reproducible as was 
anticipated. 
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Figure 11. Profile of the linear regression analysis for fresh solutions 
of powdered oxytetracycline HCl in rumen fluid. The 95% 
confidence bounds are given as dashed lines. Selected points 
from Table 5 are shown 
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Table 6. Summary of raw data and regression analysis for fresh solutions 
of compressed drug in rumen fluid 
Concentration (ug/ml) 
100 50 25 10 1 
Fluorescence intensity 
Trial 1 26.55 12.28 6.86 2.09 0.05 
25.45 13.60 6.17 2.14 0.02 
Trial 2 26.26 10.45 5.15 0.06 0.00 
26.76 11.83 5.86 1.58 0.00 
Trial 3 27.34 12.53 6.70 2.00 0.12 
27.24 15.17 7.22 2.02 0.06 
2.7% 12.7% 11.9% 48.7% 114.5% 
Regression analysis through origin 
Concentration = 3.79 x fluorescence intensity 
r = 0.994 
n = 30 
95% confidence bounds 
Slope: 3.64 < 3.79 < 3.95 
Intercept: -1.44 < 0 < 1.44 
^Coefficient of variation = = • 100. 
X 
The regression curve from Table 4 was used to measure the concentra­
tions of oxytetracycline HCl in the artificial rumen fluid medium (Equa­
tion 58) for determining the diffusion coefficient. The regression 
curve from Table 6 was used to measure the concentrations of oxytetra­
cycline HCl released from delivery prototypes #1-3. 
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Figure 12. Profile of the linear regression analysis for fresh solutions 
of compressed oxytetracycline HCl in rumen fluid. The 95% 
confidence bounds are given as dashed lines. Selected points 
from Table 6 are shown 
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Solubility of Oxytetracycline HCl in 
Artificial Rumen Fluid 
The solubility of oxytetracycline HCl in artificial rumen fluid at 
38.3°C (pH 6.7) was determined from three separate trials. The solubili­
ty, Cg = 9.7±0.1 mg/ml. The mean value for C^ was used in Equation 58 
for determining the diffusion coefficient of oxytetracycline HCl in arti­
ficial rumen fluid. It was also used in the design of delivery prototypes 
#1-3. 
Diffusion Coefficient Estimation 
The diffusion coefficient for oxytetracycline HCl in an aqueous 
medium at 38.3°C as estimated from the Nernst-Einstein equation was 
— p 
D = 5.315 X 10" cm /sec. Since the oxytetracycline HCl molecule re­
sembled a prolate ellipsoid more closely than a sphere, Equation 55 was 
o 
used to estimate the frictional coefficient. Using a = 8.1168 A, and b = 
5.4600 A, estimated from bond lengths, then = 6.2303 A. With 
(38°C) = 0.6783 x 10"^ g/cm-sec, from Equation 55, / = 80.7884 x 10 
g/sec. With T = 311.3°K, Equation 53 for large molecules becomes: 
D = 5.315 X 10 ^ cm^/sec. 
The diffusion coefficient for oxytetracycline HCl in artificial rumen 
fluid at 38.3°C estimated from the method of Hussain (1972) was D = 1.87 x 
— 6  2  10 cm /sec. From a comparative in vitro dissolution study on different 
oxytetracycline HCl capsules in water at 37°C (Butler, 1973), the percent 
drug dissolved versus time for the reference product (Pfizer Inc.) was 
37% in 6 minutes. Knowing that 250 mg capsules were used, M = .37(250 mg) 
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= 92.50 mg in 6 minutes. If 60-80 mesh drug particles were used (radius = 
2 106 ym), then A = (wt x 3)/radius = 70.755 cm . Therefore, from Equation 
57, with Cg = 9.7 mg/ml at 38.3°C; D = 1.87 x 10 ^ cmf/sec. 
The diffusion coefficient for compressed oxytetracycline HCl in 
artificial rumen fluid at approximately 38.3°C was determined experimen­
tally (Equation 58) as D = 1.96±0.57 x 10'® cm^/sec. Table 7 shows the 
data for three separate duplicate determinations at three different 
pHs. Note that when pH increased, so the diffusion coefficient increased. 
However, since rumen pHs vary from 5.0-7.0 (Phillipson, 1970), the six 
values of the diffusion coefficient in Table 7 were averaged to obtain the 
mean value and standard deviation stated above. The coefficient of varia-
tion was determined as 29.3%. = 9.7 mg/ml was used in the diffusion 
coefficient determination. Although the diffusion coefficients determined 
by the method of Hussain (1972) and experimentally were similar, the ex-
r p 
perimentally determined diffusion coefficient, D = 1.96 x 10" cm /sec, 
was used in the design of prototypes #1-3. 
Prototype #1 
The following parameters were used in the design and analysis of 
delivery prototype #1: 
= 7.79 cm/sec (velocity around delivery device) 
V = 0.6831 X 10"^ cm^/sec (water at 38°C) 
^Coefficient of variation, CV = = • 100. 
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Table 7. Experimental data for the determination of the diffusion coeffi­
cient of compressed oxytetracycline HCl in artificial rumen 
fluid at 38,3°C 
Trial pH D (10~® cm^/sec) ^ (10-4) 
1 6.48 1.49 0.16 
2.66 0.65 
2 7.00 2.00 0.51 
2.60 1.49 
3 6.08 1.29 0.25 
1.69 0.25 
D = 1.96 X 10"® cm^/sec (determined experimentally from Equation 58 
in artificial rumen fluid at 38.3°C) 
n = 0.0178 cm 
Sc = 3493.05 (v/D) 
Re = 976.03 (around a cylinder of characteristic diameter, L = 
0.8564 cm) 
h = 4.151 X 10"^ cm (from Equation 38) 
L = 6.1 cm (length of delivery slot) 
p = 1341.1 mg/cm (density of the compressed drug) 
0 = IT radians 
Cg = 9.7 mg/ml (determined experimentally at 38.3°C in artificial 
rumen fluid) 
' 0-242 cm 
V = 200 ml 
Vg = 7 ml 
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Table 8 shows the theoretical values for time, t (Equation 49), 
mass of oxytetracycline HCl released, (Equation 48), and the steady 
state release rate, J (Equation 43), for different X. Figures 13 and 14 
show the theoretical mass of oxytetracycline HCl released versus time and 
the steady state release rate versus time, respectively. 
Table 8. Theoretical release kinetics for prototype #1 
A (cm) t (days) Mr (mg) J (mg/day) 
0.020 0.00 5.14 65.19 
0.040 0.44 20.47 26.77 
0.060 1.59 46.03 19.91 
0.080 3.58 81.81 16.84 
0.100 6.50 127.79 15.05 
0.120 10.43 184.00 13.84 
0.140 15.43 250.42 12.96 
0.150 18.35 287.46 12.60 
0.160 21.55 327.05 12.29 
0.180 28.83 413,90 11.75 
0.200 37.32 510.96 11.30 
0.220 47.04 618.23 10.93 
0.240 58.02 735.72 10.61 
0.242 59.19 748.03 10.58 
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Figure 13. Theoretical and experimental mass of oxytetracycline HCl released versus time for proto­
type #1. Selected points from Table 8 are shown. Regression analysis is shown for each 
data set .  Theoret ical  data ( • ) .  Exper imental  data (A)  
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Figure 14. Theoretical and experimental release rates versus time for prototype #1. Selected 
points from Table 8 are shown. Theoretical data (•). Experimental data (A) 
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Table 9 shows the release of oxytetracycline HCl from prototype #1 
as determined experimentally in an in vitro rumen using Equation 59. 
The concentration of oxytetracycl ine HCl was determined using the regres­
sion calibration curve from Table 6. The experimental sum of mass of 
oxytetracycline HCl released, (Table 9), versus time and the average 
release rate, J (Table 9), versus time are shown in Figures 13 and 14, 
respectively. A linear regression curve (forced through the origin) 
was applied to both the theoretical and experimental data from 1 to 59 
days in Figure 13. The linear regression analysis was done to check if 
the device was zero-order according to the Brooke and Washkuhn (1977) 
theory. A zero-order device exhibits a horizontal straight line in Figure 
14 and a sloped straight line in Figure 13. Thus, a linear regression 
analysis indicates how well the data, whether theoretical or experimental, 
approximate zero-order release kinetics. 
The theoretical release kinetics of prototype #1 (Table 8) indicate 
that the delivery device should operate for approximately 59.2 days. The 
release rate, taken from the slope of the regression analysis of versus 
t (Table 8) for A 0.020 cm, is J = 13.30 mg/day (r = 0.991). 
The experimental sum of mass of oxytetracycline HCl released, EM^,in 
Figure 13 shows a plateau starting at approximately 52 days. This was an 
indication that the delivery device was terminating drug release. The 
experimental release rate, taken from the slope of the regression analysis 
of versus time (Table 9) for 59 days, is J = 16,33 mg/day 
(r = 0.960). 
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Table 9. Experimental release of oxytetracycline HCl from prototype #1 
Day My. (mg) ZMy. (mg) J (mg/day) 
1 5.84 5.84 5.84 
2 10.11 15.95 7.98 
3 19.71 35.66 11.89 
4 21.16 56.82 14.21 
5 20.91 77.73 15.55 
6 22.48 100.21 16.70 
7 26.69 126.90 18.13 
8 32.55 159.45 19.93 
10 49.37 208.82 20.88 
11 28.89 237.71 21.61 
13 36.70 274.41 21.11 
14 21.42 295.83 21.13 
15 20.12 315.95 21.06 
17 26.55 342.50 20.15 
18 19.60 362.10 20.12 
19 32.60 394.70 20.77 
20 28.71 423.41 21.17 
21 23.76 447.17 21.29 
22 15.86 463.03 21.05 
23 14.18 477.21 20.75 
24 14.47 491.68 20.49 
25 12.64 504.32 20.17 
27 19.89 524.21 19.42 
28 13.05 537.26 19.19 
30 22.35 559.61 18.65 
32 17.93 577.54 18.05 
33 4.33 581.87 17.63 
35 4.63 586.50 16.76 
37 16.45 602.95 16.30 
39 15.84 618.79 15.87 
41 50.72 669.51 16.33 
44 52.13 721,64 16.40 
46 14.10 735.74 15.99 
48 14.93 750.67 15.64 
51 23.35 774.02 15.18 
52 4.94 778.96 14.98 
54 10.75 789.71 14.62 
57 8.02 797.73 14.00 
59 2.51 800.24 13.56 
61 1.88 802.12 13.15 
63 2.30 804.42 12.77 
65 2.64 807.06 12.42 
67 2.07 809.13 12.08 
69 1.52 810.65 11.75 
71 1.74 812.39 11.44 
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Table 9. (Continued) 
Day Mr (mg) M
 Î J (mg/day) 
73 1.89 814.28 11.15 
75 2.64 816.92 10.89 
78 3.55 820.47 10.52 
80 2.90 823.37 10.29 
82 4.68 828.05 10.10 
84 5.93 833.98 9.93 
Although the experimental data in Figure 13 matched the linear re­
gression analysis quite well up to 59 days (r = 0.960), the theoretical 
fit was better (r = 0.991). 
A mean oxytetracycline HCl release rate from Figure 14 was deter­
mined by averaging the average release rates in Table 9. For 1-69 days, 
J = 17.45±3.65 mg/day. Both the mean experimental oxytetracycline HCl 
release rate and the experimental release rate taken from the regression 
analysis of Figure 13 were greater than what the theory for prototype #1 
suggested (J = 13.30 mg/day). 
Prototype #2 
The following parameters were used in the design and analysis of 
delivery prototype #2: 
= 7.79 cm/sec (velocity around delivery device) 
V = 0.6831 X 10"^ cm^/sec (water at 38°C) 
-fi p D = 1.96 X 10" cm /sec (determined experimentally from Equation 58 
in artificial rumen fluid at 38.3°C) 
n = 0.0178 cm 
70 
Se = 3493.05 (v/D) 
Re = 976.03 (around a cylinder of characteristic diameter, L = 
0.8564 cm) 
h = 4.151 X 10"^ cm (from Equation 38) 
L = 6.054 cm (length of delivery slot) 
O 
p = 1375.9 mg/cm (density of the compressed drug) 
0 = ÏÏ radians 
Cg = 9.7 mg/ml (determined experimentally at 38.3°C in artificial 
rumen fluid) 
W = 0-238 cm 
V = 200 ml 
Vg = 7 ml 
Table 10 shows the theoretical values for time, t (Equation 49), 
mass of oxytetracycline HCl released, (Equation 48), and the steady 
state release rate, J (Equation 43), for different X. Figures 15 and 16 
show the theoretical mass of oxytetracycline HCl released versus time and 
the steady state release rate versus time, respectively. 
Table 11 shows the release of oxytetracycline HCl from prototype #2 
as determined experimentally in an in vitro rumen using Equation 59. 
The concentration of oxytetracycline HCl was determined using the regres­
sion calibration curve from Table 6. The experimental sum of mass of 
oxytetracycline HCl released, (Table 11), versus time and the average 
release rate, J (Table 11), versus time are shown in Figures 15 and 16, 
respectively. A linear regression curve (forced through the origin) 
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Table 10. Theoretical release kinetics for prototype #2 
A (cm) t (days) Mr (mg) J (mg/day) 
0.020 0.00 5.24 64.70 
0.040 0.45 20,85 26.57 
0.060 1.63 46.88 19.75 
0.080 3.67 83.31 16.71 
0.100 6.67 130.14 14.93 
0.120 10.70 187.38 13.73 
0.140 15.83 255.02 12.86 
0.150 18.83 292.74 12.51 
0.160 22.11 333,06 12.19 
0.180 29.58 421.50 11.66 
0.200 38.29 520.34 11.22 
0.220 48.26 629.59 10.84 
0.238 58.34 736.80 10.56 
was applied to both the theoretical and experimental data from 1 to 59 
days in Figure 15, 
The theoretical release kinetics for prototype #2 (Table 10) indicate 
that the delivery device should operate for approximately 53,3 days. The 
release rate, taken from the slope of the regression analysis of versus 
t (Table 10) for A ^ 0,020 cm, is J = 13.48 mg/day (r = 0,991), 
The experimental sum of mass of oxytetracycline HCl released, in 
Figure 15 shows a plateau starting at approximately 63 days. Drug release 
termination was indicated at this time. The experimental release rate, 
taken from the slope of the regression analysis of EM^ versus time (Table 
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15. Theoretical and experimental mass of oxytetracycline HCl released versus time for proto­
type #2. Selected points from Table 10 are shown. Regression analysis is shown for 
each data set. Theoretical data (•). Experimental data (A) 
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Figure 16. Theoretical and experimental release rates versus time for prototype #2, Selected 
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Experimental release of oxytetracycline HCl from prototype #2 
My. (mg) ZMr (mg) J (mg/day) 
5.94 5.94 5.94 
10.40 16.34 8.17 
11.34 27.68 9.23 
10.27 37.95 9.49 
8.53 46.48 9.30 
7.28 53.76 8.96 
7.84 61.60 8.80 
8.84 70.44 8.81 
15.05 85.49 8.55 
7.01 92.50 8.41 
9.37 101.87 7.84 
3.65 105.52 7.54 
3.33 108.85 7.26 
8.90 117.75 6.93 
6.29 124.04 6.89 
6.48 130.52 6.87 
7.98 138.50 6.93 
11.97 150.47 7.17 
8.75 159.22 7.24 
12.08 171.30 7.45 
11.22 182.52 7.61 
3.85 186.37 7.45 
11.71 198.08 7.34 
8.45 206.53 7.38 
14.60 221.13 7.37 
20.93 242.06 7.56 
8.86 250.92 7.60 
36.63 287.55 8.22 
31.19 318.74 8.61 
38.86 357.60 9.17 
19.26 376.86 9.19 
18.88 395.74 8.99 
9.09 404.83 8.80 
5.93 410.76 8.56 
13.74 424.50 8.32 
6.67 431.17 8.29 
11.20 442.37 8.19 
11.69 454.06 7.97 
5.80 459.86 7.79 
8.33 468.19 7.68 
8.62 476.81 7.57 
6.05 482.86 7.43 
2.55 485.41 7.24 
2.94 488.35 7.08 
3.58 491.93 6.93 
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Table 11. (Continued) 
Day Mr (mg) ZMr (mg) J (mg/day) 
73 3.14 495.07 6.78 
75 2.22 497.29 6.63 
78 1.87 499.16 6.40 
80 1.79 500.95 6.26 
82 2.32 503.27 6.14 
84 1.46 504.73 6.01 
11) for 59 days, is J = 8.15 mg/day (r = 0.991). The experimental data 
in Figure 15 match the linear regression analysis quite well (r = 0.991) 
and is the same as the regression analysis fit for theory 
(r = 0.991). 
The mean release rate for prototype #2 was determined from Table 11 
for 1-59 days as J = 8.00±0.84 mg/day. The experimental release rate of 
prototype #2 (Figure 16) approximated zero-order more closely than the 
theoretical data as it tended to be flatter with less exponential 
decay over 59 days. Both experimental release rates, from the regression 
analysis and the mean of the average release rates (Table 11), for proto­
type #2 were less than what theory specified (J = 13.48 mg/day). 
Prototype #3 
The following parameters were used in the design and analysis of 
delivery prototype #3: 
= 7.79 cm/sec (velocity around delivery device) 
V = 0.6831 x 10"^ cm^/sec (water at 38°C) 
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D = 1.96 X 10"^ cm^/sec (determined experimentally from Equation 58 
in artificial rumen fluid at 38.3°C) 
n = 0.0178 cm 
Sc = 3493.05 (v/D) 
Re = 976.03 (around a cylinder of characteristic diameter, L = 
0.8564 cm) 
h = 4.151 X 10"^ cm (from Equation 38) 
L = 6.1 cm (length of delivery slot) 
p = 1425.6 mg/cm (density of the compressed drug) 
0 = TT radians 
Cg = 9.7 mg/ml (determined experimentally at 38.3°C in artificial 
rumen fluid) 
V = 200 ml 
Vg = 7 ml 
Table 12 shows the theoretical values for time, t (Equation 49), 
mass of oxytetracycline HCl released, (Equation 48), and the steady 
state release rate, J (Equation 43), for different X. Figures 17 and 18 
show the theoretical mass of oxytetracycline HCl released versus time and 
the steady state release rate versus time, respectively. 
Table 13 shows the release of oxytetracycline HCl from prototype #3 
as determined experimentally in an in vitro rumen using Equation 59. 
The concentration of oxytetracycline HCl was determined using the regres­
sion calibration curve from Table 6. The experimental sum of mass of 
oxytetracycline HCl released, (Table 13), versus time and the average 
release rate, J (Table 13), versus time are shown in Figures 17 and 18, 
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Table 12. Theoretical release kinetics of prototype #3 
A (cm) t (days) Mr (mg) J (mg/day) 
0.020 0.00 5,47 65.19 
0.040 0.47 21.77 26.77 
0.060 1.69 48.95 19.91 
0.080 3.80 86,99 16.84 
0,100 6.91 135,89 15,05 
0.120 11.09 195.66 13,84 
0.140 16.40 266,29 12.96 
0.150 19.51 305,68 12,60 
0.160 22.91 347,78 12,29 
0.180 30,65 440,13 11,75 
0.200 39.67 543.35 11,30 
0.220 50,00 657.42 10,93 
0.235 58.63 750,11 10.68 
respectively. A linear regression curve (forced through the origin) 
was applied to both the theoretical and experimental data from 1 to 59 
days in Figure 17. 
The theoretical release kinetics for prototype #3 (Table 12) indicate 
that the delivery device should operate for approximately 58,6 days. The 
release rate, taken from the slope of the regression analysis of versus 
t (Table 12) for X > 0,020 cm, is J = 13.63 mg/day (r = 0.991). 
The experimental sum of mass of oxytetracycline HCl released, in 
Figure 17 shows a plateau starting at approximately 63 days. Termination 
of drug release was indicated at this time. The experimental release rate, 
taken from the slope of the regression analysis of versus time (Table 
= 9.31t 
= 0.921 
40 50 
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Figure 17. Theoretical and experimental mass of oxytetracycline HCl released versus time for proto­
type #3. Selected points from Table 12 are shown. Regression analysis is shown for 
each data set. Theoretical data (•). Experimental data (A) 
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Figure 18. Theoretical and experimental release rates versus time for prototype #3. Selected points 
from Table 12 are shown. Theoretical data (•). Experimental data (A) 
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Table 13. Experimental release of oxytetracycline HCl from prototype #3 
Day Mr (mg) EMr (mg) J (mg/day) 
1 5.86 5.86 5.86 
2 4.01 9.87 4.94 
3 4.71 14.58 4.86 
4 5.81 20.39 5.10 
5 6.86 27.25 5.45 
6 8.09 35.34 5.89 
7 5.89 41.23 5.89 
8 5.98 47.21 5.90 
10 11.24 58.45 5.85 
11 6.79 65.24 5.93 
13 8.64 73.88 5.68 
14 2.95 76.83 5.49 
15 5.59 82.42 5.49 
17 11.47 93.89 5.52 
18 3.31 97.20 5.40 
19 6.47 103.67 5.46 
20 7.62 111.29 5.56 
21 10.18 121.47 5.78 
22 7.40 128.87 5.86 
23 15.32 144.19 6.27 
24 9.18 153.37 6.39 
25 4.95 158.32 6.33 
27 11.95 170.27 6.31 
28 4.14 174.41 6.23 
30 21.09 195.50 6.52 
32 28.36 223.86 7.00 
33 12.55 236.41 7.16 
35 25.98 262.39 7.50 
37 19.70 282.09 7.62 
39 11.63 293.72 7.53 
41 16.95 310.67 7.58 
44 42.19 352.86 8.02 
46 28.72 381.58 8.30 
48 67.62 449.20 9.36 
51 121.01 570.21 11.18 
52 58.34 628.55 12.09 
54 63.93 692.48 12.82 
57 28.52 721.00 12.65 
59 6.79 727.79 12.34 
61 19.72 747.51 12.25 
63 16.06 763.57 12.12 
65 6.20 769.77 11.84 
67 1.84 771.61 11.52 
69 0.95 772.56 11.20 
71 1.06 773.62 10.90 
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Table 13. (Continued) 
Day Mr (mg) ZMr (mg) J (mg/day) 
73 1.36 774.98 10.62 
75 1.39 776.37 10.35 
78 2.01 778.38 9.98 
80 0.82 779.20 9.74 
82 0.85 780.05 9.51 
84 1.07 781.12 9.30 
13) for 59 days, is J = 9.31 mg/day (r = 0.921). The experimental data 
in Figure 17 fit the linear regression analysis quite well (r = 0.921) 
but was not as good as the regression analysis fit for theory 
(r = 0.991). 
The mean release rate for prototype #3 was determined from Table 13 
for 1-59 days as J = 7.05±2.24 mg/day. The experimental release rate of 
prototype #3 (Figure 17) resembled zero-order more closely than theory as 
it tended to be flatter over 59 days. Both experimental release rates, 
obtained from the regression analysis and the mean of the average release 
rates (Table 13), for prototype #3 were less than that obtained from 
theory (J = 13.63 mg/day). 
Discussion of Observations 
Upon retrieval of prototypes #1-3 from the artificial rumens after 84 
days, no adverse external effects on the devices by the rumen environment 
were noted (Figure 8). The dental acrylic and the Silastic® were 
still intact. No seepage of the aqueous environment was noted around the 
periphery of the solid oxytetracycline HCl core. The drug core remnants 
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were still bright yellow. The delivery slot width over the middle portion 
(3-4 cm) of prototypes #2 and #3 increased by approximately 50% of the 
original width. The middle portion (3-4 cm) of the delivery slot of proto­
type #1 increased approximately by 100% of the original width. The 
increased slot width of prototype #1 probably accounted for the observed 
augmented oxytetracycline HCl release rate and decreased delivery time com­
pared to theoretical values. The increased delivery slot width was thought 
to be due to increased hydrostatic pressure within the device causing the 
slot to bulge. 
Upon opening the delivery prototypes, it was noted that there was 
still yellow drug-like material present within the devices. Instead of 
the material being located at the corners opposite the delivery slot as 
suggested by the delivery mechanism proposed by Brooke and Washkuhn (1977), 
the cavity contained a yellow granular material throughout (Figure 19). 
High concentration aqueous solutions of oxytetracycline HCl hydrolyze upon 
standing and deposit oxytetracycline crystals (Regna and Solomons, 1951). 
The granular material within the device cavity was identified as oxytetra­
cycline by an infrared spectrum obtained between 400 and 4000 cm ^ on a 
Nujol mull. 
Since there was agent still present in the cavity of the delivery 
devices (Figure 19, and such as residue in corners of the rectangular 
cavity) that was not governed by theoretical release kinetics (Equations 
43, 48, and 49), this may account for a slight slope which was observed in 
plots of the experimental data in Figures 13, 15, and 17 after 63 days. 
In Figures 14, 16, and 18, the initial experimental release rate 
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profiles did not correspond to the release rate profiles expected from 
theory. The depressed initial release rates were probably due to the loss 
of oxytetracycline HCl from around the delivery slot during the slotting 
Figure 19. Photograph of cross section of delivery device prototype 
showing yellow granular material (arrow) in the device 
cavity. Scale bar = 0.20 cm 
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process. Rough estimations of the amount of drug lost, obtained from the 
depth, width, and length of the delivery slot and the density of the com­
pressed solid drug core, indicated that approximately 20 mg of oxytetra-
cycline HCl was lost in the slotting procedure. A routine method of 
alleviating unwanted initially high release rates suggested from theory 
(Figure 5) may be offered by removing material from beneath the delivery 
orifice or by incompletely filling the device cavity. 
Table 14 summarizes the release kinetics obtained for prototypes #1-3 
and the composite of all data. Except for prototype #1, the experimental 
duration of oxytetracycline HCl release was close to that predicted by 
theory. The experimental release rates for prototypes #1-3 determined 
from the slopes of the linear regression analyses (Figures 13, 15, 17) 
show deviations from the theory of +22.8%, -39.5%, and -31.7% for proto­
type #1, prototype #2, and prototype #3, respectively. These deviations 
from theory can probably be explained by one or a combination of the fol­
lowing effects: 1) As will be seen later, there were slight differences in 
volatile fatty acid production and relative proportions of volatile fatty 
acids between the rumens containing the delivery prototypes. Differences 
between artificial rumens and other environmental factors influence the 
release kinetics. 2) The mean coefficient of variation associated with 
the concentration calibration curve (Table 6, Figure 12) was 38.1%. This 
was larger than anticipated and probably contributed greatly to the devia­
tions of the experimental release rates from theory. 3) The coefficient 
of variation for the experimentally determined diffusion coefficient for 
oxytetracycline HCl was 29.3%. This was due to the mean coefficient of 
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Table 14. Summary of oxytetracycline HCl release kinetics for prototypes 
#1-3 and of composite of all data 
Parameter 
Prototype 
#1 
Prototype 
• #2 
Prototype 
#3 
Composite 
data 
Theoretical 
t, days 59.19 58.34 58.63 58.72 
±0.43 
mg/day® 13.30 13.48 13.63 13.44 
r 0.991 0.991 0.991 0.990 
Experimental 
t, days 52 63 63 59±6 
mg/dayb 16.33 8.15 9.31 11.27 
r 0.960 0.991 0.921 0.834 
JIV,, mg/dayC 17.45 
±3.65 
8.00 
±0.84 
7.05 
±2.24 
10.84 
±5.33 
Release rate determined as the slope of the linear regression 
analysis forced through the origin of M versus t over the release time 
period. 
^Release rate determined as the slope of the linear regression analy­
sis of the experimental versus t over 59 days. 
Release rate determined from the average of the experimental release 
rates over 59 days stated as mean ± standard deviation. 
variation (28.4%, Table 4) associated with the concentration calibration 
curve (Figure 10) and the changes in the diffusion coefficient due to 
changes in pH (Table 7). Thus, the errors associated with the concentra­
tion calibration curves and environmental factors present within the arti­
ficial rumens may have influenced the experimental release rates signifi­
cantly. 
Figures 13-18 and Table 14 indicate that the delivery devices used in 
this investigation were not strictly zero-order. This was also true of 
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the original Brooke and Washkuhn (1977) device. However, since the sample 
correlation coefficients, r, for the individual experimental and theoreti­
cal linear regression analyses were high (r > 0.90), the application of 
this controlled delivery device would be acceptable in most biological 
applications where constant release kinetics are warranted. 
Prototypes #1-3 were fabricated simultaneously (same day) in order to 
assess the fabrication reproducibility. Table 14 indicates that the de­
livery devices (composite data) were fabricated in agreement with theory 
and had a low coefficient of variation (<1%) which indicated a high degree 
of reproducibility. The sample correlation coefficient for the linear 
regression analysis of the composite data was r = 0.990, indicating a 
nearly zero-order theoretical release rate. The composite experimental 
release rate (11.27 mg/day) was within 17% of that specified by theory 
(13.44 mg/day). The composite experimental regression line (forced through 
origin), 95% confidence bounds, and selected points are shown in Figure 20. 
The sample correlation coefficient for the composite experimental data was 
noticeably lower (r = 0,834) than that from theory (r = 0.990), This 
difference can be attributed to the influences discussed above (environ­
mental factors, changing h, and calibration curves). The mean experimental 
time of release (59±6 days) was within 1% of that stated by theory (58.72+ 
0.43 days). Thus, it seems that environmental effects influenced the 
reproducibility of the release kinetics of the delivery devices to a 
greater extent than the fabrication differences. Unfortunately, it was 
difficult to control the environmental effects (a similar problem would 
exist in actual device use in the animal). 
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Figure 20. Composite experimental regression line showing amount of oxytetracycline HCl released 
from prototypes #1-3. The 95% confidence bounds are given as dashed lines. Points from 
Tables 9, 11, and 13 are shown. Prototype #1 (•). Prototype #2 (o). Prototype #3 (a) 
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The mass of drug released plus the amount of material left within the 
delivery prototype cavity should equal the original amount of drug 
present. Upon opening delivery prototype #3, removing the contents and 
weighing, approximately 280 mg of material was found. The 280 mg plus the 
781 mg (Table 13) released experimentally plus the 20 mg lost during the 
slotting process equals 1081 mg. The initial weight of drug was 1.1383 g. 
Thus, there was approximately 57.3 mg (5% of initial weight) of drug un­
accounted for during the course of the experiment. This is not signifi­
cant and certainly can be explained by measurement error and/or error in­
duced by the concentration calibration curve (Table 6, Figure 12). 
To what extent the hydrolysis of oxytetracycline HCl and deposition 
of oxytetracycline within the delivery device cavity affects the release 
kinetics is not known. The solubility of oxytetracycline in an aqueous 
medium (1.1 mg/ml at 23°C- at pH 7.0; Regna and Solomons, 1951) is less 
than for oxytetracycline HCl (6.9 mg/ml at 28°C; Weiss et al., 1957). 
A depressed release rate might be expected due to increasing amounts of 
oxytetracycline deposition. This suggests a decreased availability of 
oxytetracycline HCl. Thus, a competing reaction with the dissolution-
diffusion process is present, ultimately attenuating the drug release rate. 
Since the fluorometric technique (Poiger and Schlatter, 1976) used in this 
investigation did not discriminate between oxytetracycline and oxytetra­
cycline HCl, it was difficult to determine the relative proportions of the 
drug species released. It appears, however, that the experimental release 
profiles (Figures 13-18) were dominated by the HCl form of oxytetra­
cycline. Perhaps more stable forms of oxytetracycline should be investi­
gated (calcium dioxytetracycline; Salivar, 1959) in the future. 
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In their present form, prototypes #1-3 did not administer oxytetra-
cycline HCl at the rate and/or duration required in Table 1. The proto­
types were purposely scaled down for ease of drug release monitoring and 
measurement. The results of the in vitro experiments were encouraging, 
indicating that the use of a similar controlled oxytetracycline HCl de­
livery device in the rumen of cattle is feasible. This device would be 
nearly zero-order. It is proposed that to achieve the administration 
levels in Table 1, a controlled delivery system composed of encapsulated 
oxytetracycline HCl bars be used. The individual drug bars, like those 
in Figure 8, would be assembled in a cylindrical weighted receptacle. 
This would allow drug release from the outside periphery of the cylinder. 
From the experimental results of prototypes #1-3, approximately 7 encap­
sulated solid oxytetracycline HCl bars of thickness 0.316 cm, width 0.632 
cm, and slot length 6.0 cm with n = 0.0178 cm would be necessary to 
provide 75 mg/day for 120 days. The physical constraints (2.54 cm dia­
meter x 6 cm length) of a potential controlled delivery system in the 
rumen of cattle can easily accommodate these 7 encapsulated bars. A 
controlled delivery system constructed from individual controlled delivery 
devices has the advantage that the overall release kinetics of the system 
can be changed just by insertion or withdrawal of the individual com­
ponents, making changes in release rate feasible in the field. 
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Artificial Rumen Viability 
£H 
Table 15 shows the pH data obtained for artificial rumens I-IV. 
Figures 21-24 show the pH versus time for artificial rumens III, I, II, 
and IV, respectively. No large difference in pH was noted between the 
control rumen III and the rumens containing the delivery prototypes. 
Rumen I (delivery prototype #1) shows a decreasing pH trend from approxi­
mately 23 to 42 days corresponding to a time period when an abnormal 
thickening of the stirred contents of the artificial rumen was noticed. 
The pH levels in Figures 21-24 are indicative of normal in vivo rumen 
fermentation, pH 5.0-7,0 (Phillipson, 1970). 
Volatile fatty acid production 
Tables 16 and 17 show the volatile fatty acid concentration data for 
artificial rumens I-IV. Figures 25-30 show the concentration of acetic 
acid, propionic acid, butyric acids (iso + n), valeric acids (iso + n), 
caproic acid, and phenyl acetic acid for artificial rumens I-IV. 
Oxytetracycline HCl treated artificial rumens (I + II + IV) showed 
(not significant,^ P £ 0.068) a 16.3% increase in acetic acid production 
(Table 17) compared to the control artificial rumen (III). A 0.6% in­
crease (not significant, P _< 0.965) in propionic acid production was noted 
for artificial rumens affected by oxytetracycline HCl versus the control 
artificial rumen. Administration of oxytetracycline HCl induced a 32.6% 
increase (not significant, P _< 0.032) in butyric acids (iso + n) produc-
^All tests performed at a level of significance of a = 0.01. 
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Table 15. pH data for artificial rumens I-IV 
Rumen III Rumen I Rumen II Rumen IV 
Day Control Prototype #1 Prototype #2 Prototype #3 
0 6.67 6.67 6.67 6.67 
8 6.92 6.79 6.29 6.92 
9 6.94 6.65 6.25 6.99 
10 6.74 6.57 5.97 6.98 
11 6.70 6.46 5.75 6.86 
12 7.09 6.64 6.52 7.14 
13 6.70 6.60 5.97 6.83 
14 6.42 6.48 6.74 7.05 
15 6.68 6.34 6.99 6.93 
16 6.90 6.44 7.41 7.15 
18 6.68 6.32 6.63 7.12 
19 6.68 6.15 6.78 7.07 
21 5.74 5.98 6.57 6.67 
22 6.66 5.97 7.10 6.94 
23 6.87 5.62 6.94 6.95 
25 5.64 5.92 6.34 7.15 
26 5.35 5.53 6.65 6.87 
27 5.87 5.50 6.30 6.96 
28 6.29 5.35 5.94 6.90 
29 7.13 5.44 7.39 7.28 
30 6.99 5.42 6.89 7.30 
31 6.90 5.31 6.78 7.24 
32 6.69 5.26 6.49 7.04 
33 7.00 5.30 6.48 6.94 
35 6.47 5.40 6.75 7.04 
36 7.01 5.40 7.48 7.22 
38 6.95 5.81 6.80 7.26 
40 6.42 5.21 6.68 7.05 
41 6.33 5.34 6.49 6.74 
43 6.39 6.70 7.13 6.77 
45 7.02 6.63 6.98 7.27 
47 6.59 6.89 5.30 5.81 
49 6.57 6.77 6.03 5.67 
52 6.12 6.68 6.65 6.22 
54 6.83 7.14 7.12 6.08 
56 7.11 6.72 6.84 6.33 
59 7.17 6.54 6.81 6.57 
60 6.98 6.00 6.62 5.82 
62 6.39 6.77 5.86 5.89 
65 5.80 7.04 7.08 7.05 
67 6.03 6.49 5.98 6.62 
69 6.88 6.24 5.26 5.81 
71 7.19 6.33 5.32 6.21 
73 7.26 7.12 5.95 6.99 
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Table 15. (Continued) 
Rumen III Rumen I Rumen II Rumen IV 
Day Control Prototype #1 Prototype #2 Prototype #3 
75 7.35 6.88 6.86 6.70 
77 7.42 6.00 5.47 5.95 
79 7.59 7.05 7.03 7.00 
81 8.29 7.41 7.20 7.35 
83 8.02 6.89 6.73 6.75 
86 6.96 7.08 6.97 6.88 
88 6.71 6.24 6.77 7.02 
90 6.72 5.62 6.47 6.75 
92 6.70 5.70 6.37 6.48 
tien over the control artificial rumen. Valeric (iso + n) and caproic 
acids showed 9.3% (not significant, P ;< 0.447) and 26.9% (not significant, 
P _< 0.192) increases in production, respectively, in artificial rumens 
treated with oxytetracycline HCl compared with the control rumen. 
Phenyl acetic acid production decreased 18.2% (not significant, P £ 0.142) 
in the oxytetracycline HCl treated artificial rumens in a comparison with 
the production in the control artificial rumen. 
The overall total acidity in the artificial rumens treated with oxy­
tetracycl ine HCl (1 + II + IV) increased by 11.8% (significant, P < 0.001) 
in a comparison with the control rumen (III). Significant differ­
ences in total acidity between artificial rumens also occurred: I versus 
IV (P < 0.001), II versus IV (P < 0.001), I versus III (P < 0.001), and II 
versus III (P < 0.001). Differences in total acidity between artificial 
rumens I and II (P <_ 0.035) and between IV and III (P _< 0.388) were not 
significant. 
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Figure 22. pH of rumen I: delivery prototype #1 
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Figure 24. pH of rumen IV: delivery prototype #3 
Table 16. Volatile fatty acid concentration data for artificial rumens I-IV 
Concentrations (yM/ml) 
Propi­ Iso- n- Iso- n- Phenyl 
Days Formic Acetic onic butyric butyric Lactic valeric valeric Caproic Oxalic acetic 
Hepta-
noic 
blank 0.46 0.92 0.06 1.87 
Starting 
i noculum 4.38 32.93 6.49 0.10 7.13 0.19 1.67 0.30 1.60 
Rumen I: 
Prototype 
#1 
8 0.45 34.12 10.31 0.10 9.63 0.80 2.71 0.76 1.85 
14 4.62 41.22 20.13 0.11 10.75 1.51 6.36 1.25 1.82 
21 4.36 42.43 24.62 0.09 9.23 0.92 7.46 1.31 1.72 
28 3.85 43.45 17.79 12.50 0.18 8.58 2.24 0.13 1.38 
35 5.65 77.62 25.47 0.42 17.14 1.09 1.05 10.39 3.90 0.82 2.52 
42 5.16 48.55 34.02 7.75 0.07 7.39 1.28 0.22 1.31 
49 4.86 26.58 8.90 3.39 2.55 0.50 0.17 1.01 
63 4.24 38.28 12.85 7.04 0.10 4.21 1.03 1.63 
70 4.09 28.15 14.44 2.36 2.58 0.46 1.69 
77 0.12 38.32 21.40 5.13 0.12 3.76 0.59 1.62 
84 36.00 17.53 0.10 6.39 0.59 4.69 0.64 1.97 
92 3.48 59.88 26.88 1.15 12.08 2.56 6.86 1.33 2.58 
Rumen II: 
Prototype 
#2 
8 4.54 54.96 20.37 0.58 14.02 1.57 5.75 1.25 0.12 2.01 
14 5.75 21.36 18.35 3.96 4.60 0.77 0.20 1.95 
21 5.59 35.86 19.69 4.70 3.53 0.66 0.22 2.74 
28 5.34 49.04 18.85 0.07 7.04 0.25 4.84 1.14 2.30 
35 3.95 42.36 14.79 0.07 3.98 0.22 3.52 0.70 0.85 
Table  16 .  (Cont inued)  
Propi- Iso-
Days Formic Acetic onic butyric 
42 4.76 46.69 13.80 0.06 
49 0.36 41.05 11.67 
63 5.05 36.17 12.29 
70 0.22 50.66 12.94 0.08 
77 4.50 51.95 19.94 0.10 
84 55.13 16.15 0.11 
92 34.01 13.39 0.15 
Rumen III 
Control 
8 4.04 30.25 10.94 0.31 
14 4.54 27.21 17.60 0.32 
21 0.29 42.96 27.65 0.26 
28 5.00 38.81 14.27 0.06 
35 4.75 36.42 20.78 0.21 
42 5.46 41.82 27.58 0.08 
49 3.54 35.58 17.99 0.27 
63 4.39 28.94 16.54 0.23 
77 4.41 44.19 22.76 1.02 
84 3.69 25.66 7.73 
92 0.07 24.94 6.18 0.05 
Rumen IV: 
Prototype 
#3 
8 5.19 33.33 16.17 0.24 
14 4.42 22.09 14.36 0.22 
21 4.33 27.62 14.55 0.09 
28 4.41 27.36 15.28 0.39 
Concentrations (uM/ml) 
n- Iso- n- Phenyl 
butyri c Lactic valeric valeric Caproic Oxalic acetic 
6.06 0.10 3.67 0.76 0.16 1.82 
7.92 3.97 1.11 2.68 
4.11 3.21 0.62 0.12 1.77 
12.41 0.26 5.52 1.95 2.48 
7.43 0.47 4.91 0.86 2.36 
8.86 0.81 4.01 0.71 2.28 
7.31 0.97 3.95 0.85 2.59 
7.04 0.93 2.77 0.66 2.23 
5.65 1.34 5.08 0.87 2.41 
8.12 1.44 5.54 0.80 2.35 
7.23 0.69 4.10 1.81 0.19 2.19 
5.00 0.93 3.54 0.68 1.89 
5.47 0.95 4.46 0.70 0.22 2.11 
4.05 0.81 2.94 0.66 2.12 
3.11 0.73 2.53 0.57 5.55 
5.48 2.37 4.47 1.06 2.66 
4.90 0.25 3.09 0.47 2.86 
2.22 0.65 2.41 0.33 2.72 
6.96 0.89 3.72 0.68 0.13 2.36 
4.00 0.73 4.07 0.77 2.05 
4.49 0.38 4.03 0.80 2.31 
4.48 0,82 3.94 0.83 2.24 
Table  16 .  (Cont inued)  
Concentrations (yM/ml) 
Propi- ISO- n- Iso- n- Phenyl 
Day Formic Acetic onic butyric butyric Lactic valeric valeric Caproic Oxalic acetic 
35 4.76 30.66 12.96 0.29 4.76 0.58 2.68 0.60 2.15 
42 4.48 28.54 18.60 0.29 4.88 0.68 4.28 0.85 2.50 
49 4.44 32.16 21.21 0.18 5.32 0.51 4.95 0.86 2.35 
63 4.89 23.99 12.17 5.04 3.79 0.79 0.19 2.11 
70 4.60 44.71 23.94 0.46 5.95 0.89 4.30 0.77 0.12 2.75 
77 4.44 41.30 17.13 0.37 6.36 0.67 3.80 0.73 2.56 
84 54.77 19.16 0.38 11.29 0.80 4.37 0.96 3.42 
92 3.64 33.33 13.04 0.30 3.71 0.83 2.75 0.45 3.08 
Table 17. Mean concentration levels and relative proportions of volatile fatty acids from artifi­
cial rumens I-IV 
Concentration (yM/ml) Relative proportion {% of total) 
Rumen Rumen 
I+II I+II+ I+II I+II+ 
Acid I II IV +IV III III+IV I II IV +IV III III+ 
Aceti c 42. 88 43.27 33. 32 39. ,83 34. 25 38 .53 53.3 58. 0 52. ,4 54. ,7 52. ,5 54.2 
Propionic 19. .53 16.02 16. 55 17. ,37 17. 27 17 .34 24.3 21. 5 26. ,1 23. ,8 26. ,5 24.4 
Butyric (iso+n) 8. .78 7.42 5. 87 7. .36 5. 55 6 .91 10.9 9. 9 9. ,2 10, .1 8, .5 9.7 
Valeric (iso+n) 6, .29 4.68 4. 54 5, ,17 4. 73 5 .06 7.8 6. 3 7, .1 7, .1 7, .3 7.1 
Caproic 1, .27 0.95 0. 76 0. .99 0. 78 0 .94 1.6 1. 3 1. .2 1. .4 1, .2 1.3 
Phenyl acetic 1. .76 2.24 2. 49 2, .16 2. 64 2 .27 2.2 3. 0 3, .9 3, .0 4, .0 3.2 
Total acidity 80. 51 74.58 63. 53 72, .88 65. 22 71 .05 
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Figure 25. Acetic acid concentration in artificial rumens I-IV. Rumen III: control (•). Rumen I: 
delivery prototype #1 (o). Rumen II: delivery prototype #2 (A). Rumen IV: delivery 
prototype #3 (•) 
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Figure 26. Proprionic acid concentration in artificial rumens I-IV. Rumen III: control (*). Rumen 
I; delivery prototype #1 (o). Rumen II: delivery prototype #2 (A). Rumen IV: de­
livery prototype #3 (•) 
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Figure 27. Butyric acid (iso + n) concentration in artificial rumens I-IV. Rumen III: control 
( • ) .  Rumen I :  de l i ve ry  p ro to type  #1  (o ) .  Rumen I I :  de l i ve ry  p ro to type  #2  (A ) .  
Rumen IV: delivery prototype #3 (•) 
10 20 30 40 50 60 70 Ô0 90 
Time, Days 
Figure 28. Valeric acid (iso + n) concentration in artificial rumens I-IV. Rumen III: control 
( • ) .  Rumen I :  de l i ve ry  p ro to type  #1  (o ) .  Rumen I I :  de l i ve ry  p ro to type  #2  ( A ) .  
Rumen IV: delivery prototype #3 (o) 
Figure 29. Caproic acid concentration in artificial rumens I-IV. Rumen III: control (•). Rumen 
I: delivery prototype #1 (o). Rumen II: delivery prototype #2 (A). Rumen IV: de­
livery prototype #3 (o) 
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Figure  30 .  Phenyl acetic acid concentration in artificial rumens I-IV. Rumen III: control (•). 
Rumen I: delivery prototype #1 (o). Rumen II: delivery prototype #2 (A). Rumen IV: 
delivery prototype #3 (•) 
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The means presented in Table 17 are calculated for only four experi­
mental units (artificial rumens I, II, III, and IV). Artificial rumens I, 
II, and IV were sampled twelve times, and the control (rumen III) was sam­
pled eleven times. Since the number of samples are much greater than the 
number of experimental units, the standard deviations of the mean concen­
trations of volatile fatty acids in artificial rumens I, II, and IV, com­
bined (data column 4), are better indicators of sampling error than dif­
ferences between experimental units. The standard deviations of the means, 
in Table 17 (column 4), underestimate the experimental error\ 
Since significant differences in total acidity between artificial 
rumens affected by oxytetracycline HCl occurred, independent of the level 
of oxytetracycline HCl, similar differences between more than one control 
artificial rumens would seem likely. A more conclusive experiment to 
study the effects of oxytetracycline HCl on rumen fermentation would be to 
use more artificial rumens (both with the drug and controls) and sample 
less frequently. This would minimize artifacts due to sampling error, 
and would enhance effects due to artificial rumen differences. 
Based on the limited observations, the mean concentrations of volatile 
fatty acids were not significantly different in the artificial rumens (I + 
II + IV) affected by oxytetracycline HCl in a comparison with the control 
artificial rumen (III). This suggests that the disease control effect 
theory would be followed for growth promotion and high feed efficiency if 
a similar pattern was to be observed for in vivo experiments. 
^Dr. David Cox, 124 Snedecor, Iowa State University, Ames, lA. Per­
sonal communication, 1981. 
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Since volatile fatty acid production is a function of the time after 
feeding, and diet (Phillipson, 1970), it is difficult to make an objective 
estimate on artificial rumen viability. However, note that the total 
volatile fatty acid acidity in Table 17 of artificial rumens I-IV is 
greater than the original rumen inoculum (total acidity = 50.41 yM/ml, 
Table 16). The total volatile acidity and the relative proportions of 
volatile fatty acids (Table 17) are within the ranges reported in the 
literature (Phillipson, 1970). Thus, based on these observations, it 
seems that the artificial rumens functioned viably for 92 days. 
Summary 
The viability of the artificial rumens was assessed by monitoring the 
pH and the volatile fatty acid concentrations. From the experimental data 
obtained for pH (Table 15; Figures 21-24) and volatile fatty acid concen­
trations (Table 16 and 17; Figures 25-30), the fermentation process in the 
artificial rumens seems to be similar to that found in vivo. There was 
little shift in the pH or volatile fatty acid concentrations due to oxy-
tetracycline HCl administration. 
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CONCLUSIONS 
1. A controlled release device which delivers agents at higher 
rates and longer times than currently available using other controlled 
release techniques is described. Release rates on the order of 10-100 
times that available with membrane encapsulated systems and approximately 
1000 times that available from osmotic pumps can be obtained. Delivery 
times can be made as long as necessary, the major limitation being the 
physical size of the device. The controlled release device can exhibit 
nearly zero-order release kinetics. 
2. Experimental release of oxytetracycline HCl from three controlled 
release prototypes was monitored in artificial rumens. The composite re^ 
lease time of the three delivery devices (59±6 days) deviated approxi­
mately 1% from the prescribed theoretical delivery time (58.72±0.43 days). 
The composite release rate of the three delivery devices (11.27 mg/day) 
was approximately 16% lower than the prescribed theoretical release rate 
(13.44 mg/day). These deviations from theory were reasonable when the 
effects of the biological environment and contributions of the variations 
in measurement technique were considered. 
3. The viability of the artificial rumens was determined from the 
pH and the volatile fatty acid concentrations. Based upon the limited 
data, all artificial rumens (4) were found to be viable representations 
of the in vivo system. The mean concentrations of volatile fatty acids 
in the artificial rumens containing the oxytetracycline HCl controlled 
release devices were not significantly different from the control artifi­
cial rumen. 
n o  
4. Although the experimental release of oxytetracycline HCl from 
the three controlled release prototypes was not as reproducible as expected 
from theory, the experimental results were encouraging. The use of this 
controlled release device or a unit incorporating a number of similar 
individual controlled release devices to administer oxytetracycline HCl 
in the rumen of cattle is feasible. 
m 
RECOMMENDATIONS FOR FUTURE RESEARCH 
Feasibility of using a controlled release device to administer oxy-
tetracycline HCl in the rumen of cattle was shown by monitoring oxytetra-
cycline HCl release from controlled release devices in artificial rumens. 
However, further engineering refinements and studies are necessary to en­
hance this potential for commercial use. 
Alternative means of encapsulating the active ingredient should be 
pursued. The use of dental acrylic and medical grade Silastic® resulted 
in a time consuming fabrication process. The resulting encapsulation was 
bulky. To provide a lighter, less bulky controlled release device, 
and to make production faster and more economical, an alternative materi­
al (s) can be used as long as the requirements of impermeability and bio-
compatibility are achieved. 
Because the controlled release prototypes used in this investigation 
were scaled down, the resulting release rates do not match those 
specified in Table 1. A necessary in vitro study prior to commercial 
use would involve incorporating individual controlled release bar devices 
into a cylindrical receptacle. Monitoring oxytetracycline HCl release in 
an artificial rumen from the controlled release system should indicate if 
modifications are necessary before in vivo testing. Preliminary calcula­
tions indicate that a controlled release system consisting of seven con­
trolled release bar devices can provide the necessary release kinetics 
(75 mg/day for 120 days). 
In vivo studies may proceed if this controlled release system proves 
reliable in administering oxytetracycline HCl in the artificial rumen. A 
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preliminary in vivo study might include the following: 
1. Group I: control animals (no oxytetracycline HCl) 
2 .  Group II: animals fed with oxytetracycline HCl as a premix 
3. Group III: animals where oxytetracycline HCl is administered by 
the controlled release system . 
4. Group IV: animals administered a sham controlled release system 
(no oxytetracycline HCl) 
The following parameters might be measured: 
1. Initial weight 
2. Final weight 
3. Gain (final weight - initial weight) 
4. Average daily gain 
5. Dry matter intake 
6. Crude protein intake 
7. TDN (Total Digestible Nutrients) 
8. Percent protein (crude protein/dry matter intake x 100) 
9. Percent TDN (TDN/dry matter intake x 100) 
This protocol would allow comparisons among the cattle administered 
oxytetracycline HCl via the controlled release system, the control cattle, 
and the cattle fed with a comparable amount of oxytetracycline HCl as a 
premix. 
It must be emphasized that oxytetracycline HCl was chosen as the 
agent for release only to illustrate the controlled release device design 
and application. Numerous other antibiotics, hormones and beneficial 
agents can be used in the controlled release device as long as the physi-
113 
cal characteristics of the active ingredient (solubility, diffusion 
coefficient) can be characterized. 
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APPENDIX: ARTIFICIAL FLUID COMPOSITIONS 
Table A1 shows the composition of synthetic saliva from McDougall 
(1948). Table A2 shows the composition of the saliva used in this in­
vestigation. 
Table A1. Composition of McDougall's (1948) saliva 
Salt mM/1 g/1 
NaHCOg 117 9.8 
Na2HP04'12H20 26 9.3 
NaCl 8 0.47 
KCl 8 0.57 
CaClg 0 . 2  0.04 
MgClg 0.3 0.06 
Table A2. Composition of the saliva used in current investigation 
Salt mM/1 g/1 
NaHCOg 117 9.8 
NagHPO^ 26 3.7 
NaCl 8 0.47 
KCl 8 0.57 
CaClg 0 . 2  0.04 
MgClg 0.3 0.06 
The saliva is mixed with tap water to a volume ratio of 60/40 
(saliva/tap water) and infused into the artificial rumens. 
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Table A3 shows the acid composition of the artificial rumen solution. 
The total volatile acidity was assumed to be 120 mEq/1 (Phillipson, 
1970). Artificial saliva (Table A2) was added to elevate the pH to 6.1-
6.5. This solution was used in determining the diffusion coefficient of 
oxytetracycline HCl. 
Table A3. Acid composition of artificial rumen solution 
% of total 
Acid volatile acidity ml/1 
Acetic 70 4.81 
Propionic 20 1.80 
n-Butyric 9 0.99 
iso-Butyric 1 0.11 
